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Aberrant RAS signaling, caused by activating mutations of the RAS genes (H-, K- 
and NRAS), has been implicated in approximately 30% of all human cancers with the 
vast majority of these mutations occurring in the KRAS. Approximately five percent of 
human liver cancers are attributed to activating mutations of the KRAS. Hepatocellular 
carcinoma (HCC), a common form of primary liver tumor, is one of the most common 
and aggressive tumors worldwide. Capitalizing on the growing importance and relevance 
of zebrafish, Danio rerio, as an alternate cancer model, it was used to model human HCC 
in this study. 
The Tg(lfabp-rtTA2s-M2; TRE2-eGFP-Kras G12V) line expressed eGFP-Kras 
G12V in a liver-specific manner under the control of the Tet-on system. Ectopically 
expressed eGFP-Kras G12V was predominantly localized at the plasma membrane and 
was biologically active. Based on quantitative bio-imaging and molecular markers for 
genetic and signaling aberrations, we showed that oncogenic Kras expression during 
early development caused liver enlargement, concomitant with elevated RAF/MAPK and 
PI3K/AKT signaling. Kras G12V expression in adult transgenic resulted in the 
development of HCC associated with increased RAF/MAPK signaling. Thus, this model 
could be useful as a platform for small molecule screen or the study of oncogenic Kras 
signaling.  
Like the KRAS GTPase, RhoA also acts as a key molecular switch in the signal-
transduction cascade that controls and regulates many important biological processes 
ranging from proliferation and survival, to migration. It is also implicated in many human 
cancers. While much has been learnt about their individual functions in cell and animal 
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models, the physiological/pathophysiological consequences of their signaling crosstalk in 
multi-cellular context in vivo remains undefined, especially in liver development and 
cancers. Furthermore, the roles of RhoA in RAS-mediated transformation remain 
controversial. Herein, I generated transgenic fish that expressed RhoA, constitutively 
active RhoA G14V or dominant-negative RhoA T19N in a liver restricted manner under 
the control of the Tet-on system. They were used to study the crosstalk of Kras and RhoA 
in the context of liver development and tumorigenesis.  
Double transgenic fish harboring Kras G12V and RhoA or its mutants were 
obtained by the crossing of selected transgenic lines. The oncogenic Kras-mediated liver 
overgrowth was augmented significantly by dominant-negative RhoA T19N, but was 
significantly reduced by constitutively active RhoA G14V. These changes correlated well 
with changes in hepatocyte proliferation in the respective transgenic lines. It could be, in 
part, attributed to the upregulation of Akt2 expression/activities by reduced RhoA 
signaling, and the downregulation of Akt2 expression/activities by increased RhoA 
signaling, in the respective double transgenic larvae. 
Survival studies further revealed that co-expression of dominant-negative RhoA 
T19N with oncogenic Kras increased the mortality rate (due to HCC development) 
significantly as compared to the other single and double transgenic lines. Interestingly, 
the double transgenic Tg(lfabp-rtTA2s-M2; TRE2-eGFP-Kras G12V; lfabp-rtTAs-M2- 
TRE2-mCherry-RhoA G14V) did not result in any significant increase in its survival 
compared to the Tg(lfabp-rtTA2s-M2; TRE2-eGFP-Kras G12V) despite its ability to 
downregulate Kras-mediated liver enlargement in the larvae.  
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In this study, I reported the first in vivo vertebrate animal model of Ras and Rho 
crosstalk in regulating liver development and tumorigenesis. My findings could 
eventually influence the development and use of therapeutic intervention targeting RhoA 
signaling for the treatment of RAS-driven cancers. 
Key findings: 
 I have established a zebrafish HCC model, driven by oncogenic Kras signaling, 
with potential as a platform for chemical compound library screening for drug 
development. 
 I demonstrated that the liver-specific ectopic expression of either RhoA or its 
mutant could cause the development of HCC in transgenic zebrafish. 
 I have established the first in vivo vertebrate model of crosstalk between Kras and 
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1.1 RAS superfamily of small guanine nucleotide triphosphatases (GTPases) 
Early research in the 1960s on the oncogenic Harvey murine sarcomas virus and 
Kirsten murine sarcomas virus provided vast early insight into oncogenic genetics 
elements which were later established as human HRAS and KRAS oncogene, respectively. 
They got their name RAS because of their ability to cause rat sarcomas (Cox and Der, 
2010). It was not until 1982 that HRAS, the first human mutated active oncogene, was 
identified in human cancer (Cox and Der, 2010; Shih and Weinberg, 1982). Since then 
numerous efforts were spent characterizing the RAS oncogene, identifying its role as a 
master regulator of many aspects of cell biology, including proliferation, differentiation, 
cytoskeleton reorganization, nucleocytoplasmic transport, microtubule organization, 
vesicle trafficking and gene expression (Takai et al., 2001). It also triggered future studies 
that led to the identification and characterization of many small GTPase members of the 
RAS superfamily.  
The RAS superfamily of small guanine nucleotide triphosphatases (GTPases) 
consists of monomeric G-proteins with molecular masses of 20-40 kDa and comprises 
over 150 members in humans (Figure 1.1). Many of the members are highly conserved 
among eukaryotes. They are divided into five major branches, namely the RAS, RHO, 
RAB, RAN and the ARF family, based on their sequence and functional similarities 
(Wennerberg et al., 2005). The RAB family is the largest with 61 members while RAN is 
the smallest with only one member. Each family such as the RAS family can be further 
classified into many sub-families, as illustrated in Figure 1.2. Structurally, members of 
the RAS superfamily share a conserved G domain that is made up of five sets of G box 
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GDP/GTP binding motif elements starting at the N-terminus, called G1 to G5 motifs 
(Bourne et al., 1991; Wennerberg et al., 2005). 
 
Figure 1.1: Dendrogram of Human RAS superfamily members. RAS superfamily 
members are divided into five families, namely the RAS, RHO, RAN, RAB and ARF 
family. The RAB family comprises of the largest number of members with 61 members 
(blue), followed by the RAS family with 36 members (pink), the ARF family with 27 
members (yellow), the RHO family with 20 members (green) and the smallest family 
being the RAN subfamily with only one member (underlined in red) (Colicelli, 2004). 






Figure 1.2: Dendrogram of members from the RAS family. The RAS family radial 
tree was generated using matrices derived from a ClustalW multiple sequence alignment 
of the various RAS family members (Modified from Karnoub and Weinberg, 2008). The 
H-, N-, and KRAS proteins are grouped together in a cluster. They represent the better 
characterized members of the RAS family.  
 
 
The small GTPases can be considered as binary molecular switches, cycling 
between the GTP-bound active form and the GDP-bound inactive form. The GTPases 
possess low intrinsic GTP hydrolysis activity and high affinity for free GDP and GTP 
(Wennerberg et al., 2005). The activity of the small GTPases is tightly regulated by two 
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groups of proteins, namely the guanine exchange factors (GEFs) and the GTPase-
activating proteins (GAPs). The small GTPases are activated by the GEFs which promote 
GDP release and the subsequent binding to the more abundant GTP. Once activated, the 
small GTPases can bind to different effectors and trigger cascades of signaling to elicit 
various cellular responses. The GAPs are negative regulators of the small GTPase 
signaling. The GAP serves to increase the intrinsic GTPase activity of the small GTPases, 
hydrolyzing the GTP to GDP, thus rendering the GTPase inactive (Figure 1.3). GTPases 
within each family are regulated by common and unique GEFs and GAPs, emphasizing 
the specificity and redundancy in GTPase signaling. The GTP-bound GTPases and GDP-
bound GTPases displayed significant conformation similarities except in the region of 
switch I and switch II. The differences in these two switch regions allow regulatory 








Figure 1.3: Regulation of RAS signaling networks. RAS proteins are binary molecular 
switches that cycle between the active GTP-bound state and the inactive GTP-bound 
state. They are negatively regulated by GAP proteins such as RASGAP, p120GAP, and 
NF-1. They are activated by GEF such as the Son of sevenless (SOS), Ras GTP-releasing 
proteins/factors (RasGRPs/RasGRFs). The binding of GTP activates RAS and enables its 
high affinity interactions with downstream targets, called effectors. RAS proteins act as 
signal transducers to convey and convert extracellular cues into biological responses. 
Growth factor stimulation of the receptor tyrosine kinase activates the RAS proteins, and 
through its interaction with downstream effectors initiates several signaling cascades. 
Activating mutation in codon 12 or 61 renders the RAS protein resistant to negative 
regulation by the GAP proteins, thus remains constitutively active. Mutation in codon 17 
of the RAS protein renders it resistant to GEF activity and thus acts as a dominant 
negative mutant to downregulate RAS signaling (Cox and Der, 2010).  
 
 
Post-translational modification by lipids represents another level of regulation for 
the majority of the RAS superfamily members. Many members of the RAS and Rho 
families possess a C-terminal CAAX tetrapeptide sequence (C = Cys, A = aliphatic 
amino acid and X = any amino acid) (Cox and Der, 2002; Wennerberg et al., 2005). The 
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CAAX sequence is the recognition sequence for lipid modification by farnesyltransferase 
or geranylgeranyltransferase. The lipid modified CAAX sequence coupled with an 
upstream secondary signal provides the membrane targeting signals, which determine the 
subcellular location of the small GTPases. Membrane anchoring for many members of 
the RAS super-family is a prerequisite for their activity (Olofsson, 1999). In addition, the 
activity of certain small GTPase, for example, RAB and RHO/RAC families, can also be 
regulated by guanine-nucleotide-dissociation inhibitors (GDIs). GDI does so by binding 
to the C-terminal of these small GTPases and extracting it from the membrane and 
sequestering it in its GDP-bound inactive form (Olofsson, 1999) in the cytosol. 
 
 
1.1.1 RAS family of GTPases 
The RAS family of GTPases encompasses 36 genes which encode 39 RAS 
proteins in the human genome (Karnoub and Weinberg, 2008). The RAS proteins are 
tightly regulated by the RASGAP and RASGEF proteins. To date, there are nine known 
RASGEF genes and eight RASGAP genes in the human genome (Grewal et al., 2011; 
Lahoz and Hall, 2008). Out of the 36 RAS genes, three RAS genes namely, K-, N-, HRAS 
were better characterized than other members of the family. These three members form 
the RAS sub-family in the RAS family of GTPases. These RAS proteins mainly act as 




The differential biology of the three RAS isoforms is largely attributed to their 
respective distinct membrane targeting sequences and post-translational lipid processing 
(Figure 1.4). They share a highly conserved N-terminal domain (1-165aa) with 90-95% 
identity. The C-terminal sequence (166-188/9aa), which is also known as the 
hypervariable region, differs significantly among the three members. The hypervariable 
region consists of the anchor sequences that act as the RAS trafficking signals. The 
anchor sequence is made of the CAAX motif and a secondary signal. The NRAS and 
HRAS have a single palmitoylation site (C181) and double palmitoylation sites (C181 & 
C184), respectively, as the secondary signal. In KRAS, the poly-lysine sequence (K175-
180) serves as the secondary signal (Hancock, 2003). The H-, N- and KRAS undergo 
farnesylation at the endoplasmic reticulum catalyzed by the ER-associated 
acyltransferase. The first lipid modification occurs on the cysteine residue in the CAAX 
motif. The H- and NRAS, but not KRAS, are palmitoylated at the ER and traffic through 
the Golgi to the plasma membrane. The KRAS exits the ER after the initial farnesylation 
and traffic to the plasma membrane by an uncharacterized mechanism (Hancock, 2003). 
It anchors itself to the plasma membrane through lipid modification and the poly-lysine 
sequence interaction with negatively charged head group of phosphatidylserine and 
phosphatidylinositol (Cox and Der, 2010). KRAS, like other RAS family members, needs 
to be membrane-bound for effective signaling to occur. Plasma-membrane-tethered 
KRAS can induce transformation, while mitochondrial bound KRAS can induce 
apoptosis (Bivona et al., 2006). Under normal/resting conditions, quiescent cells have 
only 5% of their total Ras proteins in the GTP-bound active form as compared to 50% 
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upon mutagenic activation (Osterop et al., 1993). Once in its GTP-bound active form, 




Figure 1.4: Domain architecture of the RAS protein and its membrane trafficking. 
(A) The three RAS proteins shared a conserved N-terminal of the first 165 amino acids, 
with 90-95% identity. They vary significantly at the C-terminus which is also known as 
the hypervariable region. The hypervariable region comprises the RAS anchor sequence, 
which consist of the CAAX motif and a secondary signal (highlighted in orange). The 
RAS anchor sequence acts as the RAS trafficking signal. The secondary signal in the H- 
and NRAS is made up of two and one palmitoylation sites, respectively. The poly-lysine 
stretch is the secondary signal in the KRAS. (B) The CAAX motif is processed in a step-
wise manner. It starts with the protein farnesyltransferase (PFTase) adding a farnesyl 
group (Farnesyl-PP) to the cysteine in the CAAX motif. The process continues at the 
endoplasmic reticulum with Rce1 removing the AAX tripeptide and conclude with the 
methylation with S-adenosylmethionine (SAM) by the Icmt. KRAS exit the ER after this 
step and traffic to the plasma membrane. The H- and NRAS are subsequently 
palmitoylated by the palmitosyltransferase (RPT), and translocate to the plasma 





1.1.1.1 Effectors of the RAS signaling 
The RAF/MEK/ERK and PI3K/AKT pathways are two well-characterized 
pathways out of the many vital signaling cascades regulated by RAS activation (Figure 
1.5).  
In the RAS/RAF/MEK/ERK pathway, the RAS is activated by the receptor 
tyrosine kinase (EGFR) through RasGEF SOS. The activated RAS recruits the RAF 
proteins to the plasma membrane where they are activated by phosphorylation. Active 
RAF phosphorylates and activates the MEK1/2 protein kinases, which in turn 
phosphorylate and activate the ERK1/2 proteins. Activated ERK1/2 proteins translocate 
to the nucleus. In the nucleus, ERK1/2 can phosphorylate and activate many transcription 
factors, triggering transcription of many growth-related proteins. It was also 
demonstrated that the MAPK signaling is both sufficient and necessary to induce cellular 
transformation in mouse cell lines (Leevers et al., 1994; Stokoe et al., 1994; White et al., 
1995). However, one study in 1996 by Khosravi-Far and co-workers demonstrated that 
the engagement of the RAF/MEK pathway is not necessary for RAS-induced 
transformation (Khosravi-Far et al., 1996).  
In the PI3K/AKT pathway, the activated RAS can activate PI3K. Activated PI3K 
converts PIP2 to PIP3. The PIP3 serves as signal/sites to recruit PH domain containing 
proteins to the plasma membrane. AKT and PDK1 are examples of proteins with PH 
domain. At the plasma membrane, the AKT protein is phosphorylated by PDK1 and 
mTORC2, which renders it catalytically active. Overactive AKT is implicated in cellular 
transformation and survival (Heron-Milhavet et al., 2011).  
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Many years of intense research on the RAS also led to the identification of many 
other RAS effectors, which play many vital roles in RAS transformation. These include 
RalGEF, phospholipase Cε, TIAM1, RIN1, ALL-1 and the RASSF (Karnoub and 
Weinberg, 2008). The RalGEF-Ral pathway was demonstrated to be sufficient for the 
RAS-mediated transformation in human cell line (Hamad et al., 2002), which could be 
attributed to their ability to promote proliferation and evade apoptosis (Chien and White, 
2003). TIAM1 knock-out mice show resistance to 7, 12 dimethylbenz(a)anthracene 
(DMBA)-induced tumorigenesis (Malliri et al., 2002). DMBA are carcinogens known to 
cause oncogenic RAS activation which resulted in skin tumorigenesis.  
 
 
Figure 1.5: Ras signaling networks. RAS proteins serve to relay extracellular cues to 
cytoplasmic signalling cascades. GTP-bound activated Ras engages effector molecules — 
belonging to multiple effector families — that initiate several signal-transduction 





1.1.1.2 RAS in tumorigenesis 
The RAS signaling cascade is mis-regulated in approximately 30% of all human 
tumors. In addition, RAS genes are the most frequently mutated oncogenes that can be 
detected in human tumors. Mutations in codons 12, 13 or 61 of any one of the three RAS, 
KRAS, NRAS and HRAS, transform them into active oncogenes. The KRAS and HRAS 
are more frequently mutated at glycine 12 while the NRAS is frequently mutated at 
glutamine 61. These activating mutations can be found in a variety of tumor types (Bos, 
1989; Karnoub and Weinberg, 2008; Pylayeva-Gupta et al., 2011). Mutations at these 
codons render the RAS GTPase unable to hydrolyse the bound-GTP to GDP and become 
locked in the active form. Mutation at Q61 prevents the proper association of a water 
molecule that is required for the hydrolysis. Mutations at G12 or G13 hinder the 
interaction of the GTPase with the GAP protein and thus prevent the proper orientation of 
Q61, resulting in the attenuation of GTP hydrolysis (Pylayeva-Gupta et al., 2011).  
The three human RAS genes (H-, K- and NRAS) share a high degree of sequence 
identity. Yet, the frequency of monogenic mutation is almost tissue and tumor-dependent 
(Janssen et al., 2005). The frequency of mutations is not evenly or randomly spread out to 
the three RAS genes. The vast majority of these mutations take place in the KRAS genes 
(Janssen et al., 2005; Pylayeva-Gupta et al., 2011) as shown in Table 1. Mutations in 
KRAS genes are more frequently observed in the cancer of organs forming the digestive 
system, with the pancreas (~60%) being highly targeted. Approximately five percent of 




Table 1: Distribution and frequency of RAS mutations in human cancers 
 
Adopted and modified from (Pylayeva-Gupta et al., 2011) - Numbers in parentheses 
indicate total unique samples sequenced. KRAS mutation frequency in liver cancers is 
highlighted in the red oval. * denotes activating mutation. 
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1.1.1.3 RAS in cell growth and survival 
 Sustaining proliferative signaling and resisting cell death are two of the many 
hallmarks of cancer (Hanahan and Weinberg, 2011), and RAS has been largely 
implicated in both the promotion of proliferation and the evasion of cell death. 
 As RAS is the main signal transducers/executors of extracellular mitogenic 
stimulation, it is not unexpected that oncogenic RAS promotes cell proliferation. After its 
identification as the first human oncogene, early work demonstrated that the ectopic 
expression of HRAS could drive the proliferation of quiescent cells (Feramisco et al., 
1984; Stacey and Kung, 1984). Moreover, it was later shown that oncogenic RAS-driven 
proliferation involves complex signaling networks that regulate expression of growth 
factors, growth factor receptors, cell cycle progression related genes. For instance, the 
expression of cyclin-D1, a G1 cyclin, was upregulated by oncogenic RAS signaling 
(Filmus et al., 1994; Liu et al., 1995). In addition, oncogenic RAS signaling also 
prolonged cyclin-D1 protein stability by preventing its degradation (Diehl et al., 1998). In 
1998, Robles and co-workers demonstrated that cyclin-D1 deficient mice had increased 
resistance to RAS-induced skin cancer (Robles et al., 1998) . 
 Apoptosis functions as one of the key mechanisms against malignancy, and the 
mis-regulation of this process is often implicated in many cancers. Apoptosis is a 
complex process, which is tightly regulated by a balance of pro-death and pro-survival 
factors. Oncogenic RAS signaling has been well-known for the erosion of pro-apoptotic 
mechanisms. Activation of RAF and PI3K pathways by RAS can downregulate pro-
apoptotic mediators and/or upregulate anti-apoptotic molecules (Pylayeva-Gupta et al., 
2011). For instance, RAF can upregulate anti-apoptotic protein BCL-2 (Kinoshita et al., 
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1995) and downregulate pro-apoptotic transcriptional repressor PAR-4 (prostate 
apoptosis response 4) (Ahmed et al., 2008). PI3K and RAF pathways were also shown to 
mediate phosphorylation of pro-apoptotic BAD (BCL-2 associated agonist of cell death) 
protein which resulted in its inactivation (Datta et al., 1997; Fang et al., 1999). Thus, 
oncogenic RAS signaling tipped the balance in favour of cellular survival.  
 
 
1.1.1.4 RAS in microenvironment remodelling and metastasis 
Inducing angiogenesis, activating invasion and metastasis are another three 
hallmarks of cancer (Hanahan and Weinberg, 2011). It is not too surprising that RAS 
oncogenic signaling has vital roles to play in these contexts too.  
 As the tumor grows, its access to oxygen and nutrients become a limiting factor in 
its quest to develop further. Also, it was well-documented that cancer cells, which are 
highly proliferative, require more nutrients than normal healthy cells. In order to gain 
more access to oxygen and nutrients, the tumor will need to induce the formation of new 
blood vessels. The vascular endothelial growth factor A (VEGFA) is a well-known target 
of RAS signaling. VEGFA is involved in the regulation of endothelial proliferation and 
formation of new blood vessels. VEGFA expression is upregulated by 
RAS/RAF/MEK/ERK signaling through the increased stabilization of the pro-angiogenic 
transcription factor, HIF1α (hypoxia-inducible factor-1α) (Lee et al., 2002; Richard et al., 
1999). VEGFA expression can also be increased via the COX-2 production of 
prostaglandins, which is caused by RAS signaling (Kranenburg et al., 2004).  
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 Clinically, metastasis of the tumor from its primary site usually represents the last 
stage of the cancers. This is when the tumor acquires the ability to invade into the 
surrounding tissues and distant organs. Metastatic cancers usually indicate unfavourable 
prognosis for the patients. The metastasis process requires the loss of cell-cell contact, 
loss of adhesion to the matrix and the acquisition of a more motile phenotype, which can 
be collectively known as epithelial-mesenchymal transition (EMT). This process usually 
requires the downregulation of E-cadherin, a cell-cell adhesion molecule, which weaken 
the cell attachment. RAS has been demonstrated to increase the expression of E-cadherin 
transcriptional repressors such as the SNAIL and SLUG, which reduces the expression of 
E-cadherin (Horiguchi et al., 2009; Schmidt et al., 2005). Another vital step is for the cell 
to lose its attachment to the extra-cellular matrix. Activated RAS has also been reported 
to downregulate the expression of integrin, a cell-matrix adhesion molecule, expression 
(Schramm et al., 2000). Taken together, activated RAS signaling can induce the 
“detachment” of the cancer cell from its primary site. Coupled with other signaling 
pathways, such as the TGFβ signaling, activated RAS can create a more metastatic 









1.1.1.5 Kras in zebrafish (Danio rerio) 
My laboratory recently demonstrated that the knockdown of Kras (gene: kras; 
NM_001003744) with morpholinos resulted in specific hematopoietic and angiogenic 
defects, including impaired expression of erythroid-specific gene gata1 (GATA binding 
protein 1) and hbbe3 (haemoglobin beta embryonic-3), reduced blood circulation and 
disorganized blood vessels. We have also established that the PI3K/Akt plays a crucial 
role in mediating Kras signaling during these processes in vivo (Liu et al., 2008). Based 
on current database search and to the best of our knowledge, there is no paralog of Kras 
gene found in the zebrafish genome.  
 A zebrafish model of embryonic rhabdomyosarcoma (ERMS), a very aggressive 
childhood cancer, was reported by Langenau and co-workers in 2007. This model was 
generated by the ectopic expression of human activated KRAS G12D under the rag2 
promoter. Another zebrafish cancer model mediated by KRAS G12D was also reported 
in 2007 by Le and colleagues. In this study, the expression of KRAS G12D is driven by 
β-actin promoter after the excision of the loxP-green fluorescence gene-loxP cassette by 
heat-shock-induced Cre recombinase expression. Four types of malignancy were reported 
in this study, namely, skeletal muscle tumors, myeloproliferative disorder, intestinal 
epithelial hyperplasia and malignant peripheral nerve sheath tumors. In another study, 
Park et al. (2008) reported the creation of a zebrafish pancreatic cancer model mediated 
by pancreas-specific expression of the Kras G12V. Collectively, they illustrated that the 




1.1.2 Rho GTPases family 
RAS homologous (Rho) GTPases belong to a distinct family within the RAS 
superfamily. They were first discovered in 1985 in the snail Aplysia (Madaule and Axel, 
1985). Rho GTPases can be characterized by the presence of a Rho-specific insert 
domain (Valencia et al., 1991), which is absent in other members of the RAS 
superfamily. To date, there are 20 mammalian members in this family that can be further 
classified into eight subfamilies (Figure 1.6A) (Vega and Ridley, 2008). Of the 20 
members in this family, RhoA, Rac and Cdc42 are the better studied and characterized 
members. They not only play important roles in regulating cell morphology and actin 
cytoskeleton but also in many other key aspects of cell biology, including gene 
expression, cell proliferation, cell survival and even the promotion of tumorigenesis 
(Sahai and Marshall, 2002). Earlier studies have shown that RhoA activation causes 
stress fiber formation, Rac1 activation results in lamellipodia formation, and Cdc42 






Figure 1.6: Rho family of small GTPases. (A) Dendrogram of the 20 Rho GTPase 
proteins. The tree demonstrates the relationship between the different family members. 
Members of the Rho GTPases family can be classified into 8 subfamilies (Heasman and 
Ridley, 2008). (B) Rho, Rac and Cdc42 control the assembly and organization of the 
actin cytoskeleton. The effects of Rho, Rac, or Cdc42 activation observed in Swiss 3T3 
fibroblasts. Activation of RhoA leads to stress fibers and focal adhesion formation. 
Activation of Rac induces lamellipodia. While the activation of Cdc42 leads to the 
formation of filopodia. Cdc42 activates Rac; hence, filopodia are intimately associated 
with lamellipodia (Jaffe and Hall, 2002). 
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Like RAS, most Rho GTPases also exist as binary molecular switches. They cycle 
between active GTP-bound form and inactive GDP-bound form. Rho GTPases are tightly 
regulated by three groups of proteins namely the GEF, GAP, and GDI (Figure 1.7). To 
date, there are 82 known GEFs, 67 GAPs and three GDIs (Vega and Ridley, 2008). 
Atypical Rho GTPases like the RhoH, Wrch-1, Chp and RhoBTB have amino acid 
substitutions that make them lose their GTPase activity and thus keeping them in the 
constitutively active state (Aspenstrom et al., 2007). These atypical Rho GTPases might 
be regulated by expression level, phosphorylation and protein-protein interactions with 
other molecules. The activity of Rho A had also been shown to be regulated by 
phosphorylation by PKA by Rolli-Derkinderen and colleagues (2005). RhoA signaling 
can also be regulated through ubiquitination. Smurf1 ubiquitin ligase had been 
demonstrated to ubiquitinate RhoA, leading to its degradation (Bryan et al., 2005; Sahai 






Figure 1.7: Regulation of Rho GTPase signaling networks. Inactive GDP bound 
GTPases reside mainly in the cytosol, maintained there by GDIs masking the C-terminal 
tail required for plasma membrane localization. Upon dissociation of the GDI, the Rho 
GTPases translocate to the plasma membrane, where they can be activated by GEFs 
(upon external stimuli). GEFs kick out the GDP and aids in the exchange for GTP which 
activates the Rho GTPase. Upon activation by GEFs, GTP bound Rho GTPases can bind 
different effector proteins, and induce downstream signaling pathways. GAPs inactivate 
the Rho GTPases by catalyzing the hydrolysis of the bound GTP, thus switching off the 
downstream signaling.  
 
 
1.1.2.1 Effectors of RhoA GTPases 
 In the last two decades, many RhoA downstream effectors have been identified by 
means of yeast two hybrid selection, affinity chromatography or specific interactions with 
active RhoA-GTP (Hall, 1998; Kaibuchi et al., 1999). Interactions between the effectors 
and the RhoGTPases, like the RhoGEFs and RhoGAP interactions, occur largely through 
the conserved switch I and II regions. This implies that the three Rho proteins, RhoA, 
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Rho B and Rho C, might share overlapping effectors (Wheeler and Ridley, 2004). 
However, there are some differences in the amino acid sequences in the Rho-binding 
domain of some of the effectors. These differences suggest that the affinity/interaction of 
effectors with the RhoGTPases can vary (Kaibuchi et al., 1999), where preferential 
binding can take place. In addition, the sub-cellular location of the Rho proteins could 
also determine its interaction with a specific group of effectors. For instance, the RhoB 
proteins are found primarily on the endosomes where it regulates endosomal transport 
(Fernandez-Borja et al., 2005).  
 ROCK (Rho-associated coiled-coiled containing protein kinase) is the first kinase 
effector of RhoA to be identified. It has been identified to be responsible for the majority 
of RhoA signaling, such as the formation of stress fiber, assembly of focal adhesion and 
actomyosin contractility (Ishizaki et al., 1996; Leung et al., 1995). There are currently 
two known ROCK proteins in the human genome, namely ROCK1 and ROCK2. They 
are multi-domains proteins with a highly conserved kinase domain at the N-terminus, a 
Rho binding domain at the C-terminus, and a coiled-coil domain sandwiched in between 
the two domains. ROCKs are serine/threonine kinases that can phosphorylate many 
different substrates upon activation (Riento and Ridley, 2003). ROCKs are key 
modulators of actomyosin formation and contractility which are essential for the 
formation of stress fibers and focal adhesion. They do so by increasing the level of 
phosphorylated myosin-light chain. ROCKs act through the inhibitory phosphorylation of 
the myosin binding subunit of the MLC phosphatase, which inactivates it (Kimura et al., 
1996). ROCKs can also phosphorylate the myosin-light chain directly (Amano et al., 
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1996). Besides the formation of the filamentous actin, ROCKs also stabilize it by the 
inactivation of cofilin through the LIM-kinase activation (Maekawa et al., 1999). 
 Other than ROCKs, another key effector of Rho in the regulation of the stress 
fiber and focal adhesion formation is the mDia (mammalian homologues of Drosophila 
Diaphanous). The combined effect of mDia and ROCK is vital for proper assembly of 
actomyosin bundles such as the stress fibers. mDia is a formin molecule that catalyse the 
nucleation and polymerization of actin monomer to form long actin filament (Narumiya 
et al., 2009). ROCKs phosphorylate the myosin molecules to activate the cross-linking 
between myosin and actin filaments, resulting in the formation of actomyosin bundles 
(Narumiya et al., 2009) . 
 Beside ROCK and mDia, many other Rho effectors were also identified. They 
include protein kinases (citron kinase, PI4p5K, protein kinase N), scaffolds (Rhotekin, 
Rhophilin), and lipid kinases (DAG kinase, phospholipase D) (Bishop and Hall, 2000). 
Some of them have also been demonstrated to be involved in the regulation of actin 
cytoskeleton reorganization. For instance, citron kinase controls actomyosin contractility 
during cytokinesis (Madaule et al., 1998). The numerous effectors of Rho indicate the 
importance of Rho signaling cascades in mediating various biological processes. 
 
 
1.1.2.2 RhoA in tumorigenesis 
Rho GTPases are involved in nearly all stages of cancer progression and were 
reported to be involved in the acquisition of unlimited proliferative potential, survival and 
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evasion from apoptosis, tissue invasion and the establishment of metastases (Vega and 
Ridley, 2008). It is not surprising as the Rho GTPases are vital in controlling many 
aspects of cell dynamics, and thus they must be tightly regulated spatially and temporally. 
 The misregulations of Rho GTPases signaling are often implicated in tumor 
progression. The RhoA expression level and activity were elevated in various types of 
malignancies, for example in liver tumors (Gomez del Pulgar et al., 2005) (Table 2). 
Studies demonstrated that over-expression of RhoA in rat hepatoma cells promotes 
invasiveness both in vitro and in vivo (Itoh et al., 1999; Yoshioka et al., 1998). RhoA has 
also been suggested to play a role in governing cell/tumor proliferation, and the 
promotion of survival and metastasis through many of its effectors. Unlike the RAS 
proteins, activating mutations of Rho GTPases have never been identified (Narumiya et 
al., 2009; Vega and Ridley, 2008). These might suggest that the up-regulation of RhoA 
expression may be enough to promote tumorigenesis (Karlsson et al., 2009). Conversely, 
these might also suggest that the activating mutant of RhoA does not yield any significant 
tumorigenic properties (Karlsson et al., 2009). Studies utilizing the overexpression of 
RhoA or its constitutively active mutants (G14V or Q61L) only exhibited little or weak 
transforming activities (Narumiya et al., 2009). 
The value of RhoA as a prognostic marker for HCC was investigated by many 
studies (Fukui et al., 2006; Li et al., 2006; Wang et al., 2007). Their results (by qPCR and 
immunobloting of patients’ tumor and peri-tumor specimen) suggested that RhoA is 
significantly overexpressed in HCC and even more in tissues with high invasive 
potential. Thus, increased levels of RhoA are associated with poor prognosis. Fukui and 
co-workers (2006) further demonstrated in their studies that not only did RhoA 
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expression level increase; the active GTP-bound form was also found to be elevated. A 
recent study by Gou and colleagues (2011) described significant increase in RhoA 
(plasma membrane bound) expression in HCC sample compared to normal liver tissue by 
proteomic analyses. They also reported that a RNAi knockdown of RhoA in HepG2 and 
HepG3 cells can lead to significant inhibition of growth, induction of apoptosis and 





Table 2: Dysregulation of Rho GTPase in human cancers 
 
Footnote: (A) represents high signaling activity, (P) represents high protein levels, whereas (R) 
represents high mRNA levels. Boxes containing (P) (A) represent high expression and high 
signaling activity. Abbreviations used are SSC (squamous cell carcinoma), HNSCC (head and 
neck squamous cell carcinoma), SCLC (small cell lung cancer), NSCLC (nonsmall cell lung 




Compelling evidence that Rho signaling might play a significant role in tumor 
progression of HCC could come from studies on the Deleted-in-liver cancer-1 (DLC-1) 
gene. DLC-1 is a Rho-specific GAP and it has been reported by many studies to be 
down-regulated in many types of human cancers, especially in cancers of the liver. One 
study reported that cells with reduced DLC-1 expression contain elevated GTP-bound 
RhoA levels, and enforced expression of a constitutively activated RhoA mimics DLC-1 
loss in promoting hepatocellular carcinogenesis in a background of null p53 and 
overexpressed Myc (Xue et al., 2008). Another study demonstrated that the DLC-1 
protein can negatively regulate the RhoA/Rho-associated coiled coil-forming kinase 
(ROCK)/myosin-light-chain (MLC) pathway, thus suggesting that the RhoA might play a 
significant role in shaping the tumorigenesis process in the absence of DLC-1 regulation 
(Wong et al., 2008). All the above findings suggest strong association of RhoA with liver 
tumorigenesis. 
On the other hand, the role of RhoA could also be inhibitory to tumorigenesis. 
One interesting study conducted by the Cantrell laboratory on mice suggested opposing 
roles for RhoA in tumorigenesis (Cleverley et al., 2000). They expressed the C3 
transferase, a bacterial toxin derived from Clostidium botulinum, in the thymus of mice. 
C3 transferase inhibits Rho signaling by ribosylating the Rho effector domain thereby 
abolishing its activation of downstream signaling cascades. It was reported that the C3 
transferase-expressing mice developed aggressive thymic lymphoma with early onset at 
an age of 4 to 8 months. Knockout of RhoB, a closely related member of the Rho GTPase 
family, also demonstrated increased susceptibility to transformation (Liu et al., 2001). 
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Knockout of Cdc42, a Rho related GTPase, in the liver of the mouse led to the 
development of hepatocellular carcinomas (van Hengel et al., 2008). ROCK, a key 
effector of RhoA, has been reported to negatively regulate epidermal growth factor 
receptors (EGFR) in colon and pancreatic cancer cells. Inhibition of ROCK by Y27632, a 
potent pharmacological inhibitor of ROCK, has been reported to enhance the activation 
of EGFR in both cell types thus resulting in increased proliferation (Nakashima et al., 
2011; Nakashima et al., 2010). Constitutively active RhoA has also been shown to inhibit 
proliferation by delaying G1 to S phase cell cycle progression and impairing cytokinesis 
(Morin et al., 2009). 
 
 
1.1.2.3 RhoA in zebrafish 
Currently, there are five RhoA gene paralogs identified. They are rhoaa, rhoab, 
rhoac, rhoad and rhoae. We have demonstrated that the knockdown of zebrafish RhoA 
(rhoab, Accession number: NP_997914.2) leads to extensive apoptosis during 
embryogenesis, resulting in overall reduction of body size and length. These defects are 
associated with reduced activation of Erk and reduced expression of anti-apoptotic bcl-2 
protein (Zhu et al., 2008). Earlier through the use RhoA morpholinos and convergence 
and extension (CE) morphants defective in Wnt signaling, we demonstrated the 
involvement of RhoA downstream of non-canonical Wnt5 and Wnt11 signaling to 
regulate CE movements through Rho Kinase and Diaphanous (Zhu et al., 2006). This 
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1.1.3 Interplay of RAS and RhoA signaling in tumorigenesis 
RAS and Rho small GTPases are key molecular switches that control cell 
dynamics, cell growth and tissue development via their distinct signaling pathways. 
Much has been learnt about their individual functions through cell and animal models but 
the physiological/pathophysiological consequences of their signaling crosstalk in multi-
cellular context in vivo remains largely unknown, especially in liver 
tumorigenesis. Furthermore, the roles of RhoA in RAS-mediated transformation and their 
crosstalk in vitro remain highly controversial. To date, the molecular mechanism of 
crosstalk between RhoA and RAS is still not well-defined. It appears to be cell type-
specific, varies with the RAS subtype, and depends on the kinetics and duration of RAS 









Table 3: Crosstalk of RAS and RhoA in transformation 
Crosstalk promotes 
/favors transformation 
Ras isoform Remarks (key findings) References 
Yes HRAS RAS increased RhoA activity, through the RAF/MAPK pathway, by 
downregulating p190GAP. Active RhoA reduces p21 Cip expression. 
(Chen et al., 2003) 
Yes Unspecified Sustained RAS signaling downregulated Rac activity which in turn 
increased RhoA activity, leading to EMT 
(Zondag et al., 
2000) 
Yes HRAS RhoA activities were required for the downregulation of p21 Cip1, 
which enable HRAS transformation. 
(Olson et al., 
1998) 
Yes HRAS Activated RhoA cooperated with activated RAF to induce 
transformation. Dominant-negative mutant RhoA 19N can reverse 
HRAS transformation. (Interestingly, the coexpression of RhoA 19N 
with HRAS V12 can restore stress fiber formation in transformed 
cells; RhoA19N is known to cause stress fiber disruption). 
(Qiu et al., 1995) 
Yes HRAS Active RhoA-GTP was selected for by sustained RAF/MAPK 
signaling, which was required for proliferation of RAS transformed 
cells. RAS transformation caused RhoA to be uncoupled from stress 
fiber regulation. 
(Sahai et al., 2001) 
Yes HRAS Constitutively activated RhoA and HRAS synergistically induced 




Yes HRAS Oncogenic HRAS signaling in cell deprived of p53 synergistically 
enhanced RhoA activity, through the p190GAP inactivation. 






Ras isoform Remarks (key findings) References 
Yes HRAS Oncogenic HRAS transformation via a RAF independent pathway 
phenocopy RhoA 63L transformed NIH3T3. This transformation by 




Yes HRAS TGF-β-ALK5 activation of RhoA was essential for the HRAS 
mediated transformation. 
(Fleming et al., 
2009) 
Yes HRAS RhoA signaling was required to downregulate p27 which facilitated 
RAS transformation. 
(Vidal et al., 2002) 
Yes  Unspecified Co-expression of activated Rho1 (RhoA) enhances activated RAS 
mediated eye growth (in vivo drosophila eye model). 
(Brumby et al., 
2011) 
No HRAS HRAS transformed fibroblast lack stress fiber and cell adhesion. 
Inactivation of the RhoA-Rock pathway may contribute to RAS 
transformation. 
(Izawa et al., 
1998) 
No KRAS Oncogenic KRAS downregulated RhoA activity, resulting in reduced 
actin filament and stress fiber. 
(Dreissigacker et 
al., 2006) 
No KRAS RhoA expression was downregulated in ki-ras transformed NIH3T3; 
Transformed NIH3T3 displayed loss of stress fibers; Enforced 
Tropomysoin expression reverted transformed phenotype through Rho 
upregulation. 
(Shah et al., 2001) 
No HRAS RAS transformation downregulated Rho activities through Gankyrin. 
Increased Gankyrin in RAS transformed cells increases RhoA and 
RhoGDI interaction, leading to inactivation of RhoA. 




None of these studies was able to establish either the direct association or the 
functional influences of the crosstalk between RAS and RhoA. Furthermore, most of 
these studies, except for the study by Brumby and co-workers in 2011, were performed in 
cell culture in vitro system. Most of these earlier studies were performed in fibroblastic 
cell type and most of them utilized the HRAS isoform in their works. Nevertheless, these 
studies might still contribute to the eventual understanding of this crosstalk.  
Recently, our laboratory has demonstrated that RhoA activates MEK/Erk pathway 
during zebrafish embryogenesis although the nature of interaction (direct or indirect) 
remains to be elucidated (Zhu et al., 2008). MEK/ERK signaling, one of the key 
downstream pathways of RAS could provide links between the interplay of RAS and 
RhoA.  
There were two interesting studies that might provide another indirect link 
between the RAS and Rho crosstalk. The first study (Motti et al., 2007) showed that p27 
expression level was reduced significantly in the presence of HRAS G12V. Study two 
(Besson et al., 2004) demonstrated that p27 can act as a negative inhibitor of the RhoA 
activation. It does so by binding to RhoA and thereby preventing its interaction with its 
GEF protein. Bringing together the two studies, it could imply that RAS down-regulates 
p27 expression, which in turn could not prevent RhoA activation. Consequently, it could 







1.2 Liver cancer 
The liver is the largest interior organ of the human body. It performs many vital 
functions essential for life such as nutrients storage, metabolism, digestion, detoxification 
and etc. Liver cancer is one of the most common and deadliest cancers worldwide. 
Primary forms of liver cancers include mainly hepatocellular carcinoma (HCC) and 




1.2.1 Hepatocellular carcinomas 
HCC is the predominant form of primary liver cancer. It is one of the most 
common solid tumors worldwide. It is the third-leading cause of death due to cancer 
worldwide with high incidences in Asia and Africa (Parkin et al., 2005). Its incidence rate 
in the West is also on the rise possibly due to the increase in hepatitis C virus infections 
(Gomaa et al., 2008). The major risk factor for developing HCC is the cirrhosis of the 
liver. Other major risk factors, many of which may be factors promoting cirrhosis are (1) 
chronic Hepatitis B and Hepatitis C viral infection, (2) alcoholism, (3) diabetes, (4) non-
alcoholic fatty liver disease and (5) exposure to aflatoxins (Gomaa et al., 2008). Curative 
therapies are limited to only one-third of the diagnosed HCC patients (Llovet et al., 2003) 
as many patients were diagnosed in the later stages of the disease.  
Sorafenib, an oral multi-kinase inhibitor that targets RAF/MEK/ERK and VGEF 
pathways, is the only molecular target therapy approved for use in advance HCC patients. 
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Sorafenib has been shown to increase overall survival significantly compared to placebo 
control in phase III clinical trial (Llovet et al., 2008). The usefulness and application of 
Sorafenib, a RAF/MAPK inhibitor, in HCC patients suggested the important role of 
RAS/RAF/MAPK signaling in mediating liver tumor progression. 
Molecular analysis reported genetic and epigenetic alterations in HCC to involve 
the dysregulation of many oncogene or tumor suppressor genes, including p53, β-catenin, 
MET, hepatocyte growth factor, E-cadherin, Cox2, MYC, and DLC-1 (Farazi and 
DePinho, 2006; Hoshida et al., 2010). Studies reporting the presence of activating 
mutations of the RAS gene in human HCC are uncommon (Wong and Ng, 2008). 
Nevertheless, overexpression of the RAS gene have been reported in human HCC 
(Nonomura et al., 1987). The significance of the RAS genes in HCC can be inferred by 
the fact that physiological inhibitors of the RAS/RAF/MEK/Erk pathway, such as the 
RAF-1 kinase inhibitory protein (RKIP) and Spred-1, have been frequently down-
regulated in human HCC (Wong and Ng, 2008). Another piece of evidence might come 
from the observation that the RAS-associated domain family (RASSF1) was frequently 
epigenetically silenced in HCC (Schagdarsurengin et al., 2003). RASSF1 is a 
downstream effector of the active RAS, which is responsible for the pro-apoptotic effect 







1.3 Zebrafish as a model in cancer biology 
1.3.1 Zebrafish as an experimental biological model 
 The zebrafish, a tiny freshwater teleost, has become widely popular as a powerful 
tool for dissecting gene function during vertebrate embryogenesis in the recent few 
decades (Deiters and Yoder, 2006). Its popularity can be attributed to its small size (three 
to four centimeters), high fecundity, rapid external development and optical clarity during 
development. Its small size greatly reduces the cost of setting up and maintaining a 
zebrafish husbandry as compared to the other well-established vertebrate model such as 
the mouse model. Under optimal conditions, a breeding pair can produce up to 200 
embryos per week. A large number of embryos can be collected which makes it suitable 
for large scale genetic analyses. The embryos developed at a rapid pace and much faster 
than the other related fish model, medaka (Lawson and Wolfe, 2011). Gastrulation is 
completed within ten hours post-fertilization (hpf). The developing embryos are optically 
clear and can be monitored real-time by use of a simple light microscope (Beis and 
Stainier, 2006; Westerfield, 2000).  
 The zebrafish is also amenable to both forward and reverse genetics (Beis and 
Stainier, 2006). Potential forward genetics amenability was the initial catalyst for 
researchers to adopt the zebrafish as a vertebrate model (Lawson and Wolfe, 2011). This 
approach utilized mutagens to generate random mutations and subsequent identification 
of the gene(s) responsible for an observable biological phenotype. Currently, N-ethyl-N-
nitrosourea (ENU) is the standard choice of most researchers because of its high 
mutagenic loads in premeiotic germ cells and ease of application. But the chemical 
mutagen method suffers from the difficulty in identifying the mutated gene involved in 
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eliciting the phenotype (Lawson and Wolfe, 2011). Retroviruses and transposon vectors 
were reported as alternatives to chemical mutagens because of their ease of identifying 
the targeted locus (Nagayoshi et al., 2008; Sivasubbu et al., 2006). They are not well 
adopted yet because of their low mutagenic rate, thus the need to generate a larger library 
of zebrafish for effective screening/analyses (Lawson and Wolfe, 2011). The forward 
genetics can also be used to screen for cancer-susceptibility genes during early 
development as many cellular processes affected in cancer are also active during 
development (Liu and Leach, 2011).  
Reverse genetics investigates the phenotypic/morphological changes of a gene of 
interest through the use of knock-out, knock-down or knock-in methods in the zebrafish 
embryo. Currently, morpholino antisense oligos (nucleic acid analogs) is the method of 
choice for most zebrafish researchers to study the gene function during embryogenesis 
through a knock-down of the gene of interest. Reduced gene expression was achieved 
through the steric hindrance blocking of the mRNA which resulted in translation blocking 
or modified pre-mRNA splicing. It was first demonstrated to work in the zebrafish in 
2000 (Nasevicius and Ekker, 2000). Targeting induced local lesions in genomes 
(TILLING) can be used to generate germline mutations in a targeted gene (Wienholds et 
al., 2002; Wienholds et al., 2003). Targeted gene inactivation by zinc finger nucleases 
was demonstrated in zebrafish, recently (Doyon et al., 2008; Meng et al., 2008). It works 
by the binding of a pair of zinc-finger nucleases to the targeted region and the subsequent 
introduction of a double strand break. Repair of the double strand break by non-
homologous end joining is occasionally imperfect, thus the introduction of insertion or 
deletions in the targeted gene (Lawson and Wolfe, 2011). Recent advancement in genome 
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modification has witnessed the introduction of the transcription activator–like effector 
(TALE) nuclease (TALENs) as a tool to create targeted mutations in the human genome 
(Miller et al., 2011). The TALENS function in a similar manner compared to the ZFN but 
have the advantage of being more predictable and specific in binding to targeted DNA 
(Boch and Bonas, 2010; Huang et al., 2011).  In 2011, two studies demonstrated the 
usefulness of engineered TALENs in modification of targeted genes in the zebrafish 
genome (Huang et al., 2011; Sander et al., 2011).  
 
 
1.3.2 Transgenesis in zebrafish 
Transgenesis is an important tool for assessing gene functions in various 
biological processes (Kwan et al., 2007). Transgenic animals are created through the 
introduction of a foreign DNA into the organism. The function and regulation of the 
introduced gene can later be studied in these animals. Transgenesis in zebrafish can be 
broadly classified into transient or stable transgenic approaches (Kikuta and Kawakami, 
2009).  
In the transient approach, gene function and regulation of the transgene is studied 
immediately after its introduction. This approach is rapid and convenient but it suffers 
from differential and mosaic expression due to the mosaic segregation of the injected 
DNA during the cleavage stage (Westerfield et al., 1992).  
Stable transgenesis refers to the germline transmission of the exogenously 
introduced transgene in the organism. Offsprings from the transgenic animal usually 
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follow an identical pattern of expression. It is because of the stable integration of the 
transgene into the genome. Stable transgenic zebrafish are more laborious to generate 
because of infrequent germline incorporation. Therefore, a large number of embryos need 
to be injected before a stable transgenic line can be obtained. The rate of germline 
transmission in zebrafish can be greatly enhanced through the use of transposase-based or 
enzyme-mediated approach such as the Tol2Kit (Kwan et al., 2007), Sce-I mediated 
transgenesis (Rembold et al., 2006) and the Tc1/mariner family transposable element 
Sleeping beauty (Davidson et al., 2003). Recently, Emelyanov and co-workers in 2006 
demonstrated that the maize Activator (Ac) / Dissociation (Ds) system is capable of 
mediating the transposase-mediated transposition of exogenous DNA into the zebrafish 
genome (Emelyanov et al., 2006). Briefly, they cloned EGFP gene under the control of 
keratin 8 promoter in between the 5’ and 3’ Ds-cis sequence. The plasmid was co-
injected together with the truncated Ac transposase mRNA. The translated Ac 
transposase mediated the transposition of the EGFP into the zebrafish genome. It was 
also shown to yield remarkable germline transmission rates in their study. Thus, the 
Ac/Ds transposase system can be used as an invaluable tool for the generation of 
transgenic zebrafish. To date, the majority of findings on tumorigenesis using zebrafish 
came from transgenic zebrafish expressing mammalian/zebrafish oncogene (Feitsma and 
Cuppen, 2008). A summary of use of the transgenic zebrafish in tumor studies is 






Table 4: Tumorigenesis in transgenic zebrafish 
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1.3.2.1 Conditional transgenic system 
Constitutively overexpressed gene products can be detrimental to the fitness of 
the transgenic animal when its expression can cause infertility or premature lethality. 
Thus, it can hinder the generation and maintenance of the animal. Conditional expression 
of the transgene allows the animals to develop healthily and only express the transgene 
when required. The different conditional systems employed in the zebrafish can be 
simply classified into two main categories, the binary system and the inducible system.  
 Binary systems such as the Cre-loxP and GAL4-UAS systems are alternative 
conditional expression systems to the inducible systems described below. The transgene 
in the transgenic animals (effector line) remains silent until it is crossed with another 
transgenic animal (activator line) carrying an activator gene. Only double transgenic 
animals will express the transgene of interest. The Cre-loxP system relies on the Cre-
recombinase to excise the sequences (reporter-stop codon cassette) flanked by the two 
loxP site (same orientation), resulting in a single loxP site. This allows the sequence 
downstream of the loxP site to be transcribed and expressed. Two studies in 2007 
reported the use of Cre-loxP system combined with the heat-shock inducible system to 
generate transgenic zebrafish (Feng et al., 2007; Le et al., 2007). The Cre-recombinase 
can also be introduced through the microinjection of Cre-mRNA into one-cell embryos, 
thus eliminating the need of crossing and maintaining of both activator and effector lines. 
Pioneering works by Scheer and Campos-Ortega successfully utilized the GAL4-UAS 
system for transgenesis in zebrafish by demonstrating the GAL4-dependent 
transactivation of the transgene under the UAS promoter. (Scheer and Campos-Ortega, 
1999). The disadvantage of most binary systems is the maintenance of at least two lines, 
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the effector and the activator lines. On the other hand, the binary system allows the 
creation of one effector line which can be crossed to several existing tissue-specific 
activator lines to achieve many double transgenic fish with different tissue-specific 
distribution of the transgene.  
An inducible system can be achieved through the use of an inducible promoter. 
The inducer can be either in the form of heat treatment or chemical treatment, thus 
achieving temporal control of expression of transgenes. The inducible system also allows 
the control of spatiotemporal expression when combined with the use of tissue specific 
promoters.  
The heat-shock promoter is frequently used as temporal control of transgene 
expression in transgenic zebrafish. On top of offering temporal control on the expression, 
it can also control the expression level and period by varying the temperature and length 
of heat treatment (Murtha and Keller, 2003). The main drawbacks of this approach are 
the low leaky expression of the heat-shock promoter and the global expression of the 
transgene without any spatial regulation (Blechinger et al., 2002; Halloran et al., 2000). 
Heat-shock inducible Cre-Lox-mediated transgenic zebrafish lines conditionally 
expressing human KRAS G12D were generated by Le and co-workers (Le et al., 2007). 
In this study, the heat-shock protein 70 (hsp70) promoter was used to drive the 
expression of the Cre-recombinase in double transgenic fish. Transactivation of the Cre 
gene was achieved after the application of heat treatment. The Cre-recombinase then 
mediated the excision of the reporter gene cassette, which resulted in the expression of 
human KRAS G12D. Heat-treated zebrafish embryos developed rhabdomyosarcoma, 
myeloproliferative disorder, intestinal hyperplasia, and malignant peripheral nerve sheath 
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tumor. A similar strategy was also employed by Feng and colleagues in 2007 to induce 
expression of mouse c-myc oncogene in the zebrafish (Feng et al., 2007). It was also 
reported that the transgenic fish developed T-cell acute lymphoblastic leukemia (T-ALL). 
All reported tumors in these two studies recapitulated the human disease both 
molecularly and pathologically.  
Another commonly used inducible system is the Tet-system. It can be divided into 
two types, the Tet-off and Tet-on system. The Tet-system is built on the negative 
regulator, Tetracycline repressor (tetR), of the tetracycline-resistance operon of the E.coli 
(Gossen and Bujard, 1992). In the presence of tetracycline, the tetR does not bind its 
operator thus allowing the transcription of tetracycline resistance genes.  
The Tet-off system was generated by fusing the tetR with the VP16 of HSV to 
form the Tet-controlled transcriptional activator (tTA). In the absence of tetracycline, 
tTA binds to the tetracycline operator-minimal promoter to stimulate transcriptional 
activity. In the presence of tetracycline, the tTA does not bind the tetracycline-operator 
and the transcription activity of downstream gene is halted (Gossen and Bujard, 1992).  
The Tet-on system was created by mutagenesis of the tTA to yield the reverse 
Tet-controlled transcriptional activator (rtTA). rtTA only binds the tetracycline operators 
in the presence of tetracycline, and drives the transcription of downstream genes (Gossen 
et al., 1995). The rtTA2s-M2, an improved version of the rtTA, is more sensitive to 
doxycycline induction and thus requires lesser amount of the inducer to achieve similar 
induction. Tissue-specific promoters are often used to drive the expression of the rtTA, 
thus allowing spatial control of expression. In the presence of tetracycline, rtTA can bind 
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to Tetracycline response element (TRE) (TRE is makes up several tetracycline operators) 
and transactivating the expression of the downstream transgene. The investigator can 
effectively control the presence or absence of the inducer. The Tet-on system has been 
reported in many organisms such as fungi (Meyer et al., 2011), mouse (Vitale-Cross et 
al., 2004), and etc. The first Tet-on system in the zebrafish was employed by Huang and 
colleagues. They demonstrated a specific strong expression of green fluorescence protein 
(GFP) in the heart, in the presence of doxycycline, under the control of the Tet-on system 
(Huang et al., 2005). Doxcycline is a more stable derivative of tetracycline. This system 
was chosen for my study because the expression and induction is strong, specific and 
reversible. Also, it can be quantitatively controlled by regulating the dosage of inducer 
used. The reversibility of this system could allow us to study regression of the tumors 
upon withdrawal of the inducer. 
The mifepristone-inducible LexPR system is a relatively new system employed 
and reported by Emelyanov and Parinov (2008) for zebrafish transgenesis. It works in a 
way similar to Tet-on. In short, tissue-specific promoters will drive the expression of the 
LexPR transactivator. In the presence of mifepristone, the LexPR transactivator will bind 
to the LexA operator and drive the expression of the downstream gene by the minimal 







1.3.3 Tumorigenesis in zebrafish 
1.3.3.1 Chemical carcinogenesis in zebrafish 
Zebrafish is emerging as one of the many promising animal models that are used 
as tools to study human diseases, particularly in cancer. These studies can be generally 
classified into four main types, namely chemical carcinogenesis, mutant lines, transgenic 
lines and xenotransplants (Stoletov and Klemke, 2008). 
It has been known for more than a century that teleost fish can develop tumors 
spontaneously or in response to various chemical carcinogens. Chemical carcinogenesis 
was the first approach used to induce tumorigenesis in zebrafish in 1965 by Mearle 
Stanton (Beckwith et al., 2000; Stanton, 1965). Subsequently, many other chemical 
carcinogenesis studies were carried out and many of these tumors were reported to 
resemble various types of human tumors at the histological level (Amatruda et al., 2002; 
Feitsma and Cuppen, 2008; Stoletov and Klemke, 2008). It was also noted that zebrafish 
have a very low incidence of spontaneous cancers and high tumorigenic response after 
chemical insults. This makes them an ideal model for chemical carcinogenesis (Stern and 
Zon, 2003). The small size of the fish also enables all major organs to be examined with 
relatively few histology sections placed on a small number of slides, thus reducing the 
histology costs involved (Spitsbergen et al., 2000a; Spitsbergen et al., 2000b). Its small 
size facilitated the housing of a large number of fish during a study, which further 
contributed to its greater statistical power over other mammalian carcinogenesis studies 
(Stern and Zon, 2003).  
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Chemically-induced tumors also resemble human tumors molecularly. Studies by 
Lam and colleagues demonstrated that the gene signatures of chemical carcinogens-
induced zebrafish liver tumors shared high degree of similarities at the molecular level 
(cell cycle, apoptosis and DNA repair genes) with human liver cancers (Lam and Gong, 
2006; Lam et al., 2006). Another comparative transcriptome study by the Zon laboratory 
also identified two conserved gene signatures found in both zebrafish and human 
embryonal rhabdomyosarcoma (ERMS). One was associated with tumor-specific and 
tissue-restricted gene expression in rhabdomyosarcoma and a second comprised a novel 
RAS-induced gene signature (Langenau et al., 2007).  
Taken together, zebrafish tumors share remarkable histological and molecular 
similarities with human tumors. Thus, these findings further validated the use of zebrafish 




1.3.3.2 Zebrafish liver cancer model 
Zebrafish have a very low spontaneous cancer incidence rate in the wild. On the 
other hand, zebrafish develop various malignancies, in particular, cancers of the liver, 
when treated with different chemical carcinogens such as Nitroso-compounds, 7-12-
dimethyl benzanthracene, N-Nitrosodimethylamine and N-methyl-N-nitro-N-
nitrosoguanidine (Goessling et al., 2007; Mizgireuv et al., 2004; Spitsbergen et al., 
2000a; Spitsbergen et al., 2000b). Chemically induced liver cancers in the zebrafish 
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resemble human liver cancer histologically, for example, the increase in cell proliferation, 
low degree of differentiation and atypical nuclear morphology (Spitsbergen et al., 2000a; 
Spitsbergen et al., 2000b).  
The first study on liver cancer in transgenic zebrafish was reported by Rekha and 
co-workers (2008). It was demonstrated that ectopic expression of the hepatitis C virus 
core protein in the liver increased HCC progression by two-fold as compared to the 
control when exposed to thioacetamide, a hepatotoxin (Rekha et al., 2008). It should be 
noted that it was not mentioned whether the transgenic fish in this study developed HCC 
in the absence of the hepatotoxin, thioacetamide. Our collaborators have recently 
established a zebrafish HCC model driven by ectopic expression of Xmrk oncogene 
under the control of the Tet-on system (Li et al., 2011). This demonstrated that transgenic 
zebrafish is a good model for studying liver cancers. 
 
 
1.3.3.3 Histological classification of liver lesions (tumors) in zebrafish 
Hepatocellular lesions of zebrafish during tumorigenesis can be classified into 
different categories. In order of increasing severity, they are cellular alterations, 
hyperplasia, hepatocellular adenoma and hepatocellular carcinomas (from less to more 
serious order). It is primarily determined by gross observation and histological diagnosis 
of the diseased fish. The primary criteria for the diagnosis are summarized in the Table 5. 




Table 5: Classification of features of liver lesion in zebrafish liver cancer studies 
Lesion / Observation Gross observation Histological observations 
Cellular alteration No significant 
differences. 
Cell larger than normal. 
Hyperplasia Enlarged liver. Retained two-cell plate arrangement. 
Enlarged hepatocytes with slight 
compression on neighboring tissue 
can be observed. 
Hepatocellular 
adenoma 
Enlarged liver, varies in 
color from normal liver. 
Hepatic plates are more than two-
cell thick with loss of structure. 
 Hepatocytes are of various sizes and 
can be seen compressing on 
neighboring tissue, retain sharp 
boundary.  
Increased mitosis can be observed. 
Hepatocellular 
carcinoma 
Enlarged liver. Hepatic plate arrangement are lost 
and replaced with multiple irregular 
and thick cell plates. 
Hepatocytes may resemble normal 
cell with various nucleus size, 
absence of sharp boundary (Figure 
1.8). 
Mitosis and invasion may be present. 




Figure 1.8: Differences between HCA and HCC. Arrows highlight the boundaries of 
the lesions. The boundary is lost in the HCC (left) as compared to the sharp boundary 
observed in the HCA sample (right). (Modified from sources: Dr Jan Spitsbergen, Oregon 





RAS is a master regulator of many cellular processes. It acts primarily as a signal 
transducer that links cell surface receptors to intracellular pathways (Pylayeva-Gupta et 
al., 2011). Aberrant RAS signaling, through the acquisition of activating mutations, are 
well known for its ability to promote tumorigenesis and is found in up to 30% of all 
human cancers. Activating mutations are frequently found on the codon 12, 13 and 61 of 
the RAS protein, with codon 12 making up the majority in HRAS (55%) and KRAS 
(85%) (Pylayeva-Gupta et al., 2011). Activating mutation diminished the ability of the 
RAS GTPase to hydrolyse the bound GTP to GDP, thus rendering it constitutively active. 
While there are three RAS isoforms, KRAS is found to be the most frequently mutated 
isoform in the human cancers with up to 85% of the cancers found with KRAS mutations 
(Karreth and Tuveson, 2009). It was suggested that the substitution of glycine 12 with 
valine in the KRAS was more potent than the substitution with glutamic acid (Pylayeva-
Gupta et al., 2011). Mutations in KRAS genes are more frequently observed in the cancer 
of the organs forming the digestive system, with the pancreas (~60%) highly targeted. 
Approximately five percent of human liver cancers were found with activating mutation 
of the KRAS gene.  
HCC is one of the most deadly primary liver cancers. It is always associated with 
poor prognosis and poor survival as most HCC were diagnosed in the later stage of the 
disease. It is ranked third in the number of deaths due to cancer, with incidence rates 
rising both in the East and the West. The progression and development of HCC is a 
complex process, which usually involves repeated cycle of necrosis-liver regeneration 
(hepatocyte proliferation) ultimately resulting in cirrhosis (Frau et al., 2010). 
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Molecularly, several altered/aberrant signaling pathways were identified and implicated 
in the development and progression of HCC. These pathways include receptor tyrosine 
kinases signaling, VEGF mediated angiogenic signaling, hepatocyte growth factor/c-
MET signaling, mitogen activated protein kinase (MAPK) signaling, PI3K/AKT/mTOR 
signaling, WNT/β-catenin pathway, c-myc amplification, iNOS/IKK/NF-kB signaling 
(Frau et al., 2010; Whittaker et al., 2010). Many of these signaling pathways either utilize 
RAS as the signal transducer (receptor tyrosine kinase: EGFR or IGFR) or the effectors 
of active RAS signaling such as the RAF/MAPK and the PI3K/AKT pathways. This 
suggests the importance of RAS signaling in mediating liver transformation. Currently, 
only one animal model of RAS-driven HCC exists, where transgenic mice expressing 
HRAS G12V together with the loss of β-catenin signaling in the liver developed HCC 
(Harada et al., 2004). Therefore, this shows that there is a lack of animal models for RAS 
driven HCC.  
The zebrafish is quickly growing in popularity as an alternative animal model for 
the study of human cancers in recent years (Amatruda et al., 2002; Beis and Stainier, 
2006; Feitsma and Cuppen, 2008; Lam and Gong, 2006). Its popularity can be attributed 
to its low cost of setting and maintenance of the zebrafish husbandry, rapid development, 
high fecundity, amenability to reverse and forward genetics, low incidence of 
spontaneous tumor, ease of application of small chemical molecule and its small size. 
Most importantly, carcinogen-treated zebrafish developed liver tumor that resembled 
human liver cancers both molecularly and histologically (Lam and Gong, 2006; Lam et 
al., 2006; Spitsbergen et al., 2000a; Spitsbergen et al., 2000b). Thus, these make 
zebrafish a good model for the study of Kras-driven HCC.  
50 
 
RhoA, a member of the RAS superfamily, has been implicated in many human 
cancers. The expression levels and activities of RhoA were found to be elevated in many 
human tumors, for example in liver cancer (Fukui et al., 2006; Gomez del Pulgar et al., 
2005; Li et al., 2006; Wang et al., 2007). This suggests the importance of RhoA in the 
development of liver malignancies. Interestingly, unlike the RAS protein, no activating 
mutations of RhoA have been reported and thus it was thought that the elevated level and 
activity of RhoA is sufficient to drive tumorigenesis. This might also suggest that the 
activating mutant of RhoA does not yield any significant tumorigenic properties 
(Karlsson et al., 2009) to the development of the neoplasia. Moreover, in vitro studies 
utilizing overexpression of RhoA or its constitutively active mutants (G14V or Q61L) 
only exhibited little or weak transforming activities (Narumiya et al., 2009). However, a 
study by Xue and co-workers in 2008 demonstrated the development of HCC in mice 
with the xenograft of liver progenitor cells (p53
 -/-
) transfected with RhoA G14V and 
Myc. This demonstrated that in a weakly transforming background of MYC and p53
 -/-
, 
the activation of RhoA was able to drive the formation of HCC.  
RAS and Rho GTPases are key molecular switches that regulate cell dynamics, 
cell growth and tissue development through distinct signaling pathways. While much has 
been learnt about their individual functions and crosstalk in in vitro studies, the 
physiological/pathophysiological consequences of their signaling crosstalk in vivo 
remains largely unknown. In addition, the roles of RhoA in RAS-mediated 
transformation and their crosstalk in vitro still remain controversial. Many in vitro studies 
have reported an elevated level of RhoA and/or RhoA activities in oncogenic RAS-
transformed cells or a requirement of RhoA signaling for RAS-mediated transformation 
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(Chen et al., 2003; Karaguni et al., 2002; Olson et al., 1998; Sahai et al., 2001; Xia and 
Land, 2007; Zondag et al., 2000). On the other hand, there are also studies that reported 
the contradictory results: the down-regulation or null requirement of RhoA/RhoA 
effectors activity in oncogenic RAS-transformed cells (Dreissigacker et al., 2006; Gupta 
et al., 2000; Izawa et al., 1998; Pawlak and Helfman, 2002). RAS transformed cells lack 
stress fibers and cell adhesion (key features of Rho activation), which demonstrated an 
inactivation of Rho-ROCK pathway in RAS transformed cells (Izawa et al., 1998). To 
date, the molecular mechanism of crosstalk between RhoA and RAS is still not well-
defined. Moreover, it appears to be cell type-specific, varies with the RAS subtype, and 
depends on the kinetics and duration of RAS activation (Chen et al., 2003), which adds to 
the complexity.  
The objectives of this study are as follows: (1) the generation of a zebrafish liver 
cancer model to study Kras-mediated liver tumorigenesis, with views to develop it into a 
platform for studying GTPase signaling, (2) to address the crosstalk of Kras and RhoA in 
liver development and tumorigenesis, and (3) to determine if the overexpression of RhoA 
can lead to liver tumor development. 
In the next chapter, I will discuss the essential materials and methods/strategies 














2.1 General molecular techniques 
2.1.1 Preparation of competent cells  
The desired strains of E.coli, namely DH5α or XL-1 blue, were used for the 
preparation of competent cells. A streak plate was carried out on an antibiotic-free LB 
plate with glycerol-stock of the bacteria and incubated overnight at 37 
o
C. An overnight 
starter culture (~ two ml) was created by inoculating an isolated colony of the bacteria 
into antibiotic-free LB broth, under aseptic conditions. Approximately 100 µl of the 
starter culture was inoculated in 50 ml of antibiotic-free LB broth and incubated at 37
 o
C 
with strong agitation (~ 250 rpm). Growth of the culture was monitored periodically with 
the absorbance measurement at 600 nm with a spectrophotometer. The incubation was 
halted when the absorbance reached 0.4 to 0.6 at 600 nm. The bacteria were harvested by 
centrifugation at 4000 rpm for 30 minutes at 4 
o
C. The clear supernatant was removed 
and the pellet resuspended in 17 ml of CCMB buffer. The suspension was incubated on 
ice for 20 minutes. The suspension was then subjected to centrifugation at 4000 rpm for 
ten minutes at 4 
o
C. The supernatant was removed and the pellet resuspended in four ml 






Approximately 10 to 50 ng of plasmid or ligation reaction mixture in less than 
10% of the total final volume were added to the competent cell suspension. The 
suspension was mixed by gentle tapping and incubated on ice for 30 minutes. The tube 
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was transferred to a pre-heated 42 
o
C heat block and incubated for one and half minutes. 
The tube was then transferred back on ice for at least one minute. One ml of antibiotic-
free LB broth was added to the suspension. The tube was then incubated at 37 
o
C with 
strong agitation for one hour. The bacteria suspension was pellet down with 
centrifugation at 14000 rpm for 30 seconds. The supernatant was removed and the pellet 
resuspended in 100 µl of antibiotic-free LB broth. The suspension was plated onto LB 
agar containing the appropriate selection markers, antibiotic and/or x-gal. The LB agar 
plate was incubated at 37 
o
C overnight. An isolated colony was selected for future use.  
 
 
2.1.3 Plasmid DNA preparation 
XL-1 blue or DH5α laboratory strains of E.coli were used. Axygen miniprep kit, 
USA was used following the manufacturer’s instruction for the purification of the 
plasmid DNA. Briefly, four ml of culture was harvested by centrifugation at maximum 
speed for one minute. The supernatant was decanted and the pellet was resuspended in 
250 µl of buffer S1 by vortexing. 250 µl of buffer S2 (lysis buffer) was added to the 
suspension and mixed by inverting the tubes several times. 350 µl of buffer S3 was added 
to the mix and mixed by gentle inverting. The suspension was cleared by centrifugation 
at maximum speed for ten minutes. The cleared supernatant was applied to the mini-prep 
column. The column was washed by wash buffer W1 and W2. Pre-heated water (~ 60
 o
C) 
was applied to the dried column and incubated at room temperature for ten minutes. The 
solution containing the DNA was collected by centrifugation at maximum speed for one 
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2.1.4 Polymerase chain reaction (PCR) 
Typically, PCR were carried out on a Bio-rad thermal cycler. A typical PCR 
reaction consisted of 5 mM Tris-HCl (pH 9.0 at 25 
o
C), 1.5 mM (NH4)2SO4 and 0.01% 
Triton® X-100, 1mM dNTPs (Promega, USA), 1.5 to 3.0 mM MgCl2, 200 nM of forward 
primer (1
st
 base, Singapore), 200 nM of reverse primer (1
st
 base, Singapore) and 
approximately 50 ng to 100ng of template DNA. The cycling parameters were as 
followed: one cycle of five minutes at 95 
o
C, 20 to 30 cycles of 95 
o
C for 15 seconds; 50 
to 68
 o
C for 15 to 30 seconds (temperature used dependent on the melting temperature of 
primer pair); 72 
o
C for one minute per kilo base of template, and one cycle of 72
 o
C for 
ten minutes. All PCR products were analyzed by agarose gel electrophoresis. The 
products were visualized by staining the DNA with Sybr-safe dye (Invitrogen, USA) and 
the use of an UV transilluminator. The documentation of the gel was performed by Bio-







2.1.5 DNA sequencing and sequence analysis 
Sequencing reaction was performed with the BigDye® terminator v3.1 kit 
(Applied Biosystems, USA). Typically, a five μl reaction was performed. Two μl of 
BigDye was added to three μl of solution containing 100 ng to 300 ng of DNA and 1 μM 
of primer. The sample was subjected to thermal cycling of 95 
o
C for 30 seconds and 68 
o
C for two minutes. The product was purified by sodium acetate/ethanol precipitation. 30 
μl of 95% ethanol was added to the five μl reaction. The mixture was transferred to a 
fresh microfuge tube containing one μl of 3 M sodium Acetate, pH 5.2, and incubated on 
ice for 30 minutes. The precipitated DNA was spun down by centrifugation at 14,000 
rpm for 20 minutes. The pellet was washed with 70% ethanol and dried on a 55 
o
C heat-
block. The pellet was sent to the sequencing facilities, DSB, NUS for the further analysis. 
Sequencing results were analyzed by software like BLAST 




2.1.6 DNA purification from agarose gel or PCR or restriction digestion 
QIAquick Gel extraction kit (Qiagen, USA) was used for DNA purification. DNA 
fragment, separated on a 1.0 to 1.5% agarose gel/1ppm Sybr safe DNA gel stain, was 
excised carefully with a scalpel. Three volumes of Buffer QG were added to one volume 
(by weight 100 mg -100 μl) of gel and the mixture was heated at 60 oC to dissolve the 
gel. One gel volume of isopropanol was added to the sample and mixed. The mixture was 
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applied to the QIAquick column and centrifuged to enable binding of DNA to the 
column. The column was washed with buffer QG and Buffer PE, and DNA eluted with 
pre-heated (65 
o
C) water.  
For PCR/RE reactions clean-up, five volumes of Buffer PB were added to one 
volume of the reaction mix and applied to the QIAquick column. The column was 
washed with Buffer PE and dried by centrifugation. The bound DNA was eluted with 
pre-heated (65 
o
C) water.  
 
 
2.1.7 Restriction endonuclease (RE) digestion/reaction 
All restriction endonucleases used in this study were from New England Biolabs, 
USA, unless otherwise stated. Reactions were set-up and incubated according to the 
manufacturer’s recommendations. Double digestions or sequential digestions were also 
performed according to manufacturer’s recommendation. Restriction endonuclease 
reactions were used primarily to generate “sticky” ends for cloning purposes or the 
identification of “positive” clones.  
 
 
2.1.8 DNA ligation reaction  
DNA ligation was performed using the DNA ligation kit from New England 
BioLabs, USA. Typically, a ten μl reaction was prepared according to the manufacturer’s 
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recommendation. The reactions were incubated overnight at 4 
o
C. The molecular ratio of 
vector to DNA fragment (insert) was kept at 1:3 to 1:10. Half of the reaction mix was 
used for transformation with chemically treated competent cells. 
 
 
2.1.9 In vitro mRNA synthesis for microinjection (Ac mRNA) 
The pAc SP6 plasmid was a kind gift from Dr Parinov, TLL. The plasmid was 
linearised with BamHI restriction endonuclease and gel-purified. The linearised DNA 
fragment was used as a template for mRNA synthesis using the mMESSAGE 
mMACHINE™ SP6 Kit (Ambion, Applied Biosystems, USA). One µg of linearised 
DNA was set-up in a 20 µl reaction according to the manufacturer’s protocol, and 
incubated at 37 
o
C for two hours. The mRNA was purified by Lithium chloride 
precipitation. The mRNA was quantified by nanodrop spectrophotometer and stored in 





2.2 Tet-on eGFP-Kras G12V transgenic line 
The Tet-on liver-specific oncogenic Kras transgenic was generated by Dr Liu 
Xingjun. It was later characterized by me as part of my PhD thesis. Briefly, restriction 
enzymes linearized plasmids, namely the TRE2-eGFP-Kras G12V cassette and the lfabp 
promoter-rtTAs-M2 cassette, were co-injected into the one-cell stage embryo. The 
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injected embryos were screened for the integration of the plasmids in their genome. 
Selected larvae were grown up to adulthood. The adult fish were rescreened by out-
crossing with wild-type fish. It was done to identify the founder generation when the 
genetic materials had successfully integrated in the germline. One founder fish was 
identified. The F1 progeny of this founder fish was raised up to adulthood. 
Characterization and experiments were performed using the progeny from the F1 
generation. The strategy employed is illustrated in Figure 2.1. 
 
 
Figure 2.1: Schematic diagram of the Tet-on system employed. (A) The rtTA is 
expressed in a liver specific manner directed by the lfabp promoter. In the absence of 
doxycycline, the rtTA does not bind the TRE2. Therefore there is no expression of the 
eGFP-Kras G12V in the liver. (B) In the presence of the doxycycline, the rtTA binds to 







2.3 Generation of RhoA transgenic lines  
The Ac/Ds transposase system was utilized for the creation of the RhoA 
transgenic lines. Five primary plasmids were used for the generation of the secondary 
plasmid, pDS-LF-rtTA2s-M2-TRE2-mCherry-RhoA plasmids. The five primary plasmids 
were pDS-vector and pDs(cry:C-LOP:Ch) vector (a kind gift from Dr Parinov, TLL), 
pLF-rtTA2s-M2 vector (a kind gift from Dr Zhen HuiQing, NUS), pCS 2+ -RhoA (wt or 
G12V or T19N) vectors (kind gifts from Dr Jane Zhu, NUS), pTRE2 vector (Clontech 
Taraka, USA), The LF of the pLF-rtTA2s-M2 refers to the lfabp promoter. DNA 
fragments were subcloned directly using appropriate REs or PCR/RE digestion to 
generate appropriate “sticky” ends. RE sites were introduced or deleted using site-
directed mutagenesis kit (Stratagene, USA). Briefly, the RhoA fragment was subcloned 
into pTRE2 vector by PCR/RE/ligation to yield pTRE2-RhoA vector. mCherry fragment 
was then subcloned from the pDs(cry:C-LOP:Ch) vector into the pTRE2-RhoA vector by 
PCR/RE/ligation to yield pTRE2-mCherry-RhoA. Subsequently, the TRE2-mCherry-
RhoA fragment was subcloned into pDS vector by RE/ligation to yield pDS-TRE2-
mCherry-RhoA vector. Site-directed mutagenesis was performed on the pLF-rtTA2s-M2 
vector to add an additional XhoI restriction site. The LF-rtTA2s-M2 fragment was 
subcloned into the pDS-TRE2-mCherry-RhoA vector to yield the pDS-LF-rtTA2s-M2-
TRE2-mCherry-RhoA vector. The pDS-LF-rtTA2s-M2-TRE2-mCherry-RhoA (Figure 
2.2) vector was subsequently used for the transgenesis by microinjection. (RhoA refers to 






Figure 2.2: Schematic representation of the plasmid and the Tet-on system 
employed in the generation of RhoA transgenic lines. (A) Systematic representation of 
the pLF-rtTAs M2-TRE2-mCherry-RhoA used in this study. (B) The rtTA protein is 
driven by the liver-specific promoter, lfabp promoter. In the absence of doxycycline, the 
rtTA does not bind the TRE and thus no transactivation of the mCherry-RhoA gene. (C) 
In the presence of doxycycline, the rtTA binds the TRE and transactivate the mCherry-
RhoA gene. RhoA denotes: RhoA, constitutively active RhoA G14V or dominant 






Table 6: List of primers used for the construction of pDS-LF-rtTA2s-M2-TRE2-
mCherry-RhoA 
Name of Primers Sequence (5’-3’) Target/Remarks 
mCherryfwdBamHI CCG GAT CCC GCC ACC ATG GTG AGC 
AAG GGC GAG 
mCherry 
mCherryrevBamHI CCG GAT CCC TTG TAC AGC TCG TCC 
ATG CC 
mCherry 
RhoAfwdBamHI CCG GAT CCA TGG CAG CAA TTC GCA 
AGA AGC 
RhoA  
RhoArevNotI CCG CGG CCG CTC ACA GCA GAC AGC 
ATT TGT TGC 
RhoA 
LF-SDM ACT ATA GGG CGA ACT CGA GCT CCA 
CCG CG 
To insert XhoI 
into pLF-rtTA 
vector 
LF-SDM CGC GGT GGA GCT CGA GTT CGC CCT 
ATA GT 




Micro-injection was performed using the micro-injector from World Precision 
Instrument, USA. Embryos were collected and aligned on an agarose-coated petri-dish. A 
total of 2.3 nl, containing 25 to 30 pg of plasmid DNA, 200 to 300 pg of transposase 
mRNA and 0.01% phenol red, was microinjected directly into the cell of the embryo at 
the one-cell stage. The surviving embryos were screened at 1 dpf for mCherry 
expression. mCherry positive larvae were raised separately from the mCherry negative 
larvae. Founder fish screening was carried out by out-crossing the adult fish with wild-
type fish. The resulting progeny was analyzed for mCherry expression under a 
fluorescence microscope to determine the presence of germ-line integration of the 
transgene. Four founders were identified in the Tg(lfabp-rtTAs-M2; TRE2-mCherry-
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RhoA) line. One founder each was identified in the Tg(lfabp-rtTAs-M2; TRE2-mCherry-
RhoA G14V) and Tg(lfabp-rtTAs-M2; TRE2-mCherry-RhoA T19N), respectively. The 
process of creation and screening are summarized in the Table 7. Progeny from one of the 
four founders from the Tg(lfabp-rtTAs-M2; TRE2-mCherry-RhoA) line was chosen to be 
used for the rest of this study because of its higher expression. The F1 generation fish 
from the founder were raised to maturity and the rest of the study was conducted using 
the generations after F2. 
 
Table 7: Summary of transgenesis of RhoA transgenic lines 
Genotype  Total number 
of fish that 
survived more 
than 3mths  







RhoA  144  61  4  6.56% 
RhoA G14V  48  15  1  6.67% 
RhoA T19N  44  15  1 6.67% 
 
 
2.3.1 Induction of transgene expression 
Typically, the induction of transgene in the embryos was performed with 
doxycycline 20 μg/ml at 2 dpf. Sorting of larvae according to genotypes were carried out 
at 4-5 dpf using an inverted fluorescence microscope from Zeiss, Germany. The larvae 
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were sorted to various genotypes based on the presence of different reporter gene(s) 
expressed in their liver after induction. The reporter genes used are eGFP and mCherry. 
eGFP and mCherry fluorescence proteins are used to label oncogenic Kras G12V 
transgene and various RhoA (wt/mutants) transgenes, respectively. Table 8 provides a 
summary of the transgenic lines created and used in this study. 
 
Table 8: Summary of the transgenic lines created and used  
Name Transgene Biological effects 
Tg(lfabp-rtTA2s-M2; 
TRE2-eGFP-Kras G12V) 
eGFP-Kras G12V Constitutively active mutant of Kras, 
Insensitive to GAP activities 
Tg(lfabp-rtTAs-M2; TRE2-
mCherry-RhoA) 





Dominant-negative mutant of RhoA; 
Prevent activation of other RhoA; 
Bind GEF and sequester them from 





Constitutively active mutant of 
RhoA Insensitive to GAP activities 
Footnote: All transgenic lines express the transgene in a liver-specific manner under the 
influence of the Tet-on system. 
 
 The induction of the transgene into the respective adult transgenic fish was 
achieved with the application of 10 μg/ml of doxycycline unless otherwise stated. Change 
of water was carried out every other day with the fresh application of doxycycline during 
induction. All tanks were maintained in the dark throughout the treatment. The density of 
the zebrafish was kept at five fish to one liter of water. Aeration was provided by the use 
of an air-pump. The zebrafish were fed brine-shrimp twice daily. The large scale 
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inductions were carried out to determine the oncogenicity of the transgene(s) in the adult 
liver. The flow chart in Figure 2.3 summarized the experimental set-up. Eight different 
combinatory genotypes were studied. Each genotype was divided the treatment and 
control group with 40 fish in each group. The treatment group was subjected to 
doxycycline induction at 10 μg/ml and the control group was not treated (zero μg/ml). 
The water was changed every other day and dosed with doxycycline where applicable. 
Death events were (1) dead and rotten, (2) fresh dead and (3) near death fish. The fresh 
dead fish were fixed immediately for histological analysis whiles the near dead were 
sacrificed and fixed for histological analysis. Not all dead/sacrificed fish were examined 
histologically because of the constraint in resources. 
 
 
Figure 2.3: Flow chart of induction treatment. Eight different genotypes were studied. 
Each genotype was separated in two groups, 40 fish each. One group was subjected to 





2.4 Maintenance of zebrafish 
2.4.1 Crossing of selected transgenic/wild-type line 
Wild-type and transgenic zebrafish were raised and maintained under standard 
laboratory conditions (Salas-Vidal et al., 2005). For the collection of embryos, a two tank 
system (inner tank with mesh which sits in a plastic tank) was used. Breeding pairs of 
female zebrafish and male zebrafish were placed in the inner tank separated by a plastic 
divider. The spawning tanks were kept in the photo-period room (14 hours of dark, 10 
hours of light) to stimulate spawning. The plastic dividers were removed in the morning 
to enable spawning. Embryos were collected and cleaned by the use of a strainer. 
Embryos were then transferred to petri-dishes with egg water (60 μg/ml; Red Sea Salt, 
USA) and raised at 28 
o
C. The development stages are presented in this thesis as days 
post-fertilization (dpf). Feeding started at four dpf for the larvae with powdered fish 
flakes and egg yolk solution. Brine shrimp were given from six dpf. The larvae were 
raised in a stand-alone tank until 14 to 20 dpf before they were transferred to the system. 
 
 
2.5 Western analysis with zebrafish larvae 
2.5.1 Protein extraction from zebrafish larvae and adult liver 
Five dpf larvae were harvested for Western analysis. Approximately 50 larvae 
from each genotype were collected in 1.5 ml tubes. Excess water was removed by careful 
pipetting. The larvae was either lysed immediately or stored in -80 
o
C for future analysis. 
Larvae were lysed in RIPA buffer [50 mM Tris-HCl, 150 mM NaCl, 0.75 mM EDTA, 
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1% sodium deoxycholate, 1% Triton X-100, 0.2% NaF, 0.1% SDS, 25 mM β-glycerol 
phosphate, 5 mM Na Orthvanadate, 1X protease inhibitor cocktail (Roche, USA), pH 
7.3]. Approximately 2.5-3.0 µl of RIPA lysis buffer was added per larva. The larvae were 
grinded using a pellet pestle for at least two minutes. The resulting mixtures were 
incubated on ice for at least 30 minutes before centrifugation at 14000 rpm for 20 
minutes at 4 
o
C. The supernatant was collected. Lysate protein concentration was 
estimated with BCA protein assay (Piercenet, USA), according to manufacturer’s 
instructions.  
Adult fish were sacrificed and dissected. The livers were carefully extracted, 
transferred into clean tube and weighed. The liver tissue was snap-freezed in liquid 
nitrogen immediately. It was either stored in -80 
o
C or processed immediately for protein 
extraction. The liver tissue was lysed in T-per (Piercenet, USA) supplemented with 
proteinase inhibitor, with 25 -30 µl used per mg of liver tissue. The livers were grinded 
using a pellet pestle for at least two minutes. The resulting mixtures were incubated in the 
cold with strong agitation for two hours before centrifugation at 14000 rpm for 20 
minutes at 4 
o
C. The supernatant was carefully collected without the top oil layer. The 
total protein concentration was estimated with BCA protein assay (Piercenet, USA).   
 
 
2.5.2 Protein concentration estimation 
For BCA protein assay, the lysate was diluted ten times with the lysis buffer. 200 
µl of the pre-prepared BCA reagent was added to a well containing 25 µl of the diluted 
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sample (in a 96-wells plate). The plate was incubated at 37
 o
C for 30 minutes. It was 
cooled to room temperature before analysis by a microplate reader (Bio-rad, USA) at 562 
nm. The concentration was estimated to a BSA standard curve in the assay. The samples 
were denatured at 90 
o
C for three minutes in Laemmli buffer (50 mM Tris/ HCl pH 6.8, 
1% (v/v) 2-mercaptoethanol, 2% SDS, 0.1% Bromphenolblue, 10% Glycerol).  
 
 
2.5.3 SDS-PAGE and Western blotting 
The lysate was resolved on an 8% or 10% or 12% polyacylamide gel using the 
mini protean II electrophoresis apparatus (Bio-rad, USA). The resolving gel contains 8 or 
10 or 12% acrylamide, 0.375 nm TRIS-HCl pH8.8, 0.001% SDS, 0.001% APS, 0.001% 
TEMED. The stacking gel contains 5% acrylamide, 0.125 mM Tris-HCl pH 6.8, 0.001% 
SDS, 0.001% APS and 0.001% TEMED. Electrophoresis was performed at 50 mA/gel 
for 1 hour at room temperature in SDS-running buffer (18.6 mM Tris, 144 mM glycine 
and 0.075% SDS). A wet transfer was performed in an ice-cold transfer buffer (25 mM 
Tris, 192 mM glycine, 0.01% SDS and 20% methanol) at 100 V for 90 minutes.  
 
 
2.5.4 Detection of the protein of interest 
After transferring, the PVDF membrane was blocked in blocking solution (5% 
BSA in TBST) for one hour at room temperature. The blot was probed with the 
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appropriate primary antibody (Table 9) diluted in blocking solution at 4 
o
C, overnight 
with gentle agitation. Blot was washed three times with TBST, for five minutes each. 
After that, the blot was incubated in diluted HRP-conjugated secondary antibodies 
(Sigma, USA) for one hour at room temperature with gentle shaking. The blot was 
washed three times with TBST, for five minutes each. Detection was carried out with 
enhanced chemiluminescence (ECL) substrates (Piercenet, USA) and X-ray film (Kodak, 
USA and Fuji, Japan). For re-probing of membrane with another primary antibody, the 
blot was stripped with stripping buffer (25mM Glycine-HCl, pH2.0, 1% SDS). The 
membrane was washed in two changes of stripping buffer, for 15 minutes each. After 
which, the blot was washed with TBST six times, for five minutes each. Blot was re-
block with blocking buffer for one hour at room temperature with gentle shaking before 











Table 9: Antibodies used in Western analysis and immunostaining   
Name Source Applications/dilutions 
Anti-p-ERK1/2 Sigma, USA Western/ 1:1000 
Immunostaining/ 1:1000 
Anti-ERK1/2 BD Transduction, USA Western/ 1:1000 
Anti-p-AKT2 Genscript, USA Western/ 1:1000 
Anti-AKT2 Genscript, USA Western/ 1:1000 
Anti-p-p21 Santa Cruz, USA Western/ 1:1000 
Anti-p21 Santa Cruz, USA Western/ 1:1000 
Anti-β-actin Sigma, USA Western/ 1:1000 
Anti- Cox IV Cell Signaling Technology, 
USA 
Western/ 1:1000 
Anti-GAPDH Cell Signaling Technology, 
USA 
Western/ 1:1000 
Anti-PCNA Santa Cruz, USA Immunostaining/ 1:75 
Anti-pH3 Millipore, USA Immunostaining/ 1:200 
Anti-mouse Horse radish 
peroxidase 
Sigma, USA Western/ 1:2500 
Anti-rabbit Horse radish 
peroxidase 
Sigma, USA Western/ 1:2500 








2.6 Active Ras pull-down assay 
2.6.1 Preparation of Glutathione-GST-RBD conjugates 
BL21 E.coli harboring GST-RBD (Ras binding domain) or GST bacterial 
expression vectors were inoculated into five ml of LB broth containing ampicillin and 
grown overnight at 37
 o
C with strong agitation. One ml of the starter culture was 
inoculated into 200 ml of LB ampicillin and incubated at 37 
o
C with strong agitation until 
the O.D. of the culture reached 0.5 to 0.6 at 600 nm. The expression of the GST protein 
or the GST-RBD was induced by addition of 0.1 M IPTG followed by incubation at room 
temperature with strong agitation for 20 hours. The culture was harvested by 
centrifugation at 4000 rpm for 30 mins at 4 
o
C. 50 ml and 100 ml of culture were 
collected as bacterial pellet for the GST-RBD and GST, respectively. Lysis and capturing 
of the GST-RBD or GST was performed on ice with ice-cold buffer. Five ml of lysis 
buffer [1x PBS, 1% Trition-X100, DTT (0.15 g/ml) and protease inhibitor (one tablet per 
100 ml; Roche, USA)] was added per pellet and resuspended. The resuspended solution 
was transferred to 15 ml falcon tube and subjected to sonication at 20% amplitude for 
three minutes (Pulse: three second on and nine second off). The cell debris was removed 
by centrifugation for 30 minutes at 5500 rpm at 4 
o
C. Supernatant was then transferred to 
a fresh 15 ml falcon tube. 150 μl of glutathione agarose bead (GE healthcare life science, 
USA) was added and the mixture incubated at 4
 o
C with gentle rotation for one hour. The 
supernatant was removed by centrifugation and the pellet was washed thrice with 1X 
PBS with 0.1% triton-X100, followed by two washes with 1X PBS. The beads were 
resuspended in 150 μl of 1X PBS. The concentration of purified beads was estimated by 
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2.6.2 Pull-down of active Ras 
 Total larval lysate was obtained as described in Section 2.5.1. The protein 
concentration was adjusted with RIPA buffer to achieve equal concentration among the 
different samples. 25 μg of the purified GST-RBD or GST was added per reaction. The 
suspension was incubated at 4 
o
C with gentle rotation for one hour. The beads were 
collected by centrifugation at 200 rpm for one second. The beads were washed three 
times with 750 μl of RIPA buffer. The beads were resuspended in 2X Laemmli buffer 
and heated at 90 
o
C for five minutes. The mixture was cooled on ice and pulse-
centrifuged. The supernatant was resolved on a SDS-PAGE and analysed by Western, 
probing for eGFP-Kras protein with anti-Kras and anti-eGFP antibody. 
 
 
2.7 Cryostat sectioning 
Embryos of selected stages were fixed in 4% paraformaldehyde at 4 
o
C overnight. 
Fixed embryos were washed three times with 1X PBST for five minutes each. Washed 
embryos were embedded in 1.5-2.0% agarose/5% sucrose. Agarose embedded embryos 
were stored in excess amount of 30% sucrose solution at 4 
o
C, overnight or until the 
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agarose blocks sink to bottom of the container, for equilibrations. Agarose blocks were 
mounted onto metal stands using OCT (Lecia, USA) for cryostat sectioning. Sections of 
10 µm were cut using a cryostat (Lecia, USA). Sections were mounted onto positively 
charged slides (Fisher scientific, USA). Slides were dried on a 40 
o
C hotplate for 2-3 





2.7.1 Immunofluorescence of cryostat sections 
Slides were washed in 1X PBS for five minutes. The sections on the slide were 
blocked and permeablised with 5% goat serum/PBS/0.3% Triton-X 100 for two hours at 
room temperature. The blocking solution was removed by carefully blotting with filter 
paper. Primary antibodies (Table 9) in blocking solution were applied and slides placed in 
a humid chamber. Incubation in primary antibodies was performed at 4 
o
C overnight. The 
slides were washed in 1X PBS for three times, for five minutes each. Secondary 
antibodies (fluochrome conjugated) were applied and incubated at room temperature for 
two hours. Slides were washed twice in 1X PBS for five minutes each, and counter-
stained with DAPI. The slides were mounted with fluorsave (Calbicom, USA). Images 
were captured with Zeiss LSM 510 Meta microscopy or Lecia TCS SP5x. For slides that 
did not require immunostaining, they were stained with DAPI and mounted for imaging 





2.8 Confocal imaging of larvae for volumetric analysis 
Six dpf larvae were fixed in 4% PFA at 4 
o
C overnight with gentle agitation. 
Fixed larvae were washed three times in 1X PBST, for five minutes each. Larvae were 
cleared in 50% glycerol in PBS through a progressive increment of glycerol from 10% to 
50%. Larvae were stored overnight in 50% glycerol/PBS/2.5% DABCO at 4 
o
C before 
use. Larvae were mounted in aqueous mounting media (50% glycerol, 1X PBS, 7.5% 
gelatin, 2.5% DABCO) for documentation. The larvae were arranged on glass bottom 
petri-dishes with the left side of the larvae facing the glass bottom. Images (Z-stack) were 
documented by Lecia MP 5x microscopy. Image processing was subsequently performed 
with IMARIS (Bitplane, USA), which enabled the estimation of the liver volume of the 
larvae. Briefly, the z-stack images were converted to suitable Imaris format. The z-stack 
images were viewed in the surpass model and the surfaces were created using the 
fluorescence signals. The volume occupied by the 3D model (based on the fluorescence 
signal) was estimated by the Imaris. 
 
 
2.9 Histological analysis 
Adult fish were anaesthetized in 0.5% phenoxyethanol and sacrificed. The fish 
were cut open at the belly and the skin on the left side of the fish removed. Bouin’s 
fixative (saturated picric acid: formalin (37%): acetic acid, 15:5:1) was pumped into the 
fish body through the mouth with the use of a syringe. The swim bladders were deflated 
and the whole fish were fixed in Bouin’s fixative for four days at room temperature. The 
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fixed samples were washed with ddH2O. The fixed samples were then washed in changes 
of 70% ethanol (EtOH) for twice a day for four days. The samples were dehydrated 
through a series of ethanol in the following sequence: 70% EtOH for one hour; 90% 
EtOH for two hours; 95% EtOH for one hour; 100% EtOH for two hours; 100% EtOH 
for one hour; 100% EtOH for one hour; 50% EtOH/50% Histoclear for 30 mins; 
Histoclear-I for 1.5 hours; Histoclear-II for overnight; Paraffin-I for two hours; Paraffin-
II for four hours; Paraffin-III for overnight. The samples were embedded in paraffin. Five 
μm thick sections were cut from the block using a microtome and mounted onto a 
positively charged glass slide (Fisher Scientific, USA). Sectioning of paraffin blocks and 




2.9.1 Immuno-histochemistry of paraffin section 
2.9.1.1 De-wax of paraffin section 
Sections were deparaffined and rehydrated by running it through the following 
sequence: Histoclear – ten minutes; Histoclear – ten minutes; 100% EtOH – five minutes; 
100% EtOH – three minutes; 90% EtOH – three minutes; 70% EtOH – three minutes; 
50% EtOH – three minutes; ddH2O – three minutes; ddH2O – three minutes. 





2.9.1.2 Immuno-histochemistry of paraffin section 
Deparaffined and rehydrated slides were subjected to heat based antigen retrieval. 
Briefly, rehydrated sections were soaked in antigen unmasking solution (10mM Sodium 
Citrate Buffer pH 6.0, 0.5% Tween 20 or Tris-EDTA pH9.0, 0.5% Tween 20) and heated 
up to a boil (high power) and maintained at sub-boiling temperature for 10 to 15 minutes 
(medium high power) in a microwave (Sanyo, Japan).The sections were allowed to cool 
on the bench for 30 minutes. The slides were rinsed once with TBS. Endogenous 
peroxidases were blocked using 0.5% hydrogen peroxide in TBS or DAKO endogenous 
blocking solution at room temperature for 15 minutes. The slides were rinsed thrice with 
1X TBST. The tissue sections were blocked in blocking buffer (10% goat serum in 
TBS/1% BSA) for one hour at room temperature. Primary antibody (Table 9) diluted in 
1% BSA/TBS were applied and the slides were incubated at 4 
o
C overnight. The slides 
were washed three times with 1X TBST for five minutes each. HRP polymer (Dako, 
Denmark) was applied and the slides were incubated at room temperature for 30 minutes. 
Slides were washed twice with 1X TBST and once with 1X TBS for five minutes each. 
DAB staining buffer was applied and incubated at room temperature. Color development 
was monitored carefully under a microscope. The reaction was stopped by rinsing the 
slides with water. Hematoxylin counter stain was applied according to manufacturer’s 
recommendation (Sigma, USA). Tissue sections were dehydrated and mount 
permanently. Documentation of the colorimetric staining was performed using the Zeiss 
Axioskop2 microscope. 
For immuno-fluorescence study, the peroxidase blocking step was omitted and the 
HRP polymer was replaced with fluorochrome conjugated secondary antibodies. The 
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section was mounted with fluorsave. Documentation of the staining was performed using 




2.9.2 Slides/histological diagnosis  
The H&E stained slides were diagnosed by Dr. Jan Spitsbergen of Oregon State 
University, U.S.A, based on criteria stated in Table 5. 
 
 
2.10 Statistical test 
 T-test was used for testing of differences in mean between two 
populations/samples. Fisher exact test was used for analysis of the comparisons of liver 
lesions caused by the various genotypes. Log rank test was employed for the analysis of 















3.1 Characterization of Tg(lfabp-rtTA2s-M2; TRE2-eGFP-Kras G12V) 
3.1.1 Controlled liver-specific expression of eGFP-Kras G12V 
 The founder fish, Tg(lfabp-rtTA2s-M2; TRE2-eGFP-Kras G12V), harboring the 
eGFP-Kras G12V transgene was created by Dr Liu Xingjun as described in Section 2.2. I 
aimed to investigate whether the eGFP-Kras G12V transgene is exclusively expressed in 
the liver after induction. The F1 fish were out-crossed with wild-type fish. Embryos were 
collected, treated with doxycycline at 2 days post-fertilization (dpf) and they were 
allowed to develop until 6 dpf. The enhanced green fluorescent protein (eGFP) was used 
as a reporter for oncogenic Kras expression, which can be detected with fluorescence 
microscopy. After induction by doxycycline, the eGFP expression was observed 
exclusively in the liver of the larvae (Figure 3.1).  
 
Figure 3.1: eGFP expression in transgenic larva after induction. Application of 
doxycycline induced the expression of eGFP-Kras G12V transgene in the liver of the 6 
dpf larva, specifically.  
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3.1.2 Ectopically expressed eGFP-Kras G12V resided at the plasma membrane 
predominantly  
 In order to determine the cellular distribution of eGFP-Kras G12V, eGFP positive 
transgenic larvae were cryostat-sectioned for confocal fluorescence microscopy analysis. 
I demonstrated that the eGFP-Kras G12V were enriched at the plasma membrane (Figure 
3.2). It is known that the sub-cellular localization of RAS proteins can determine its 
interaction with different effectors, thus eliciting different signal outputs. RAS-GTP has 
been shown to translocate to the plasma membrane predominantly after stimulation by 
growth factors (Augsten et al., 2006).  
 
 
Figure 3.2: Plasma membrane bound eGFP-Kras G12V. Confocal images of cross-
section of eGFP-positive transgenic 6 dpf larva. The ectopically expressed eGFP-Kras 
G12V proteins (green) were predominantly distributed to the plasma membrane. Section 






3.1.3 Oncogenic Kras G12V was expressed as an eGFP-tagged protein and retained 
its ability to interact with its effectors  
I investigated whether the introduced oncogenic Kras protein is expressed as an 
eGFP-fusion protein and whether it retains its ability to interact with its effectors. To do 
so, doxycycline-treated larvae were screened and separated into the GFP positive and 
GFP negative groups. The GFP negative group (wild-type siblings) was used as a control. 
Both groups of embryos were lysed and whole embryo lysate samples were collected. 
The samples were subjected to Western analysis with both anti-Kras and anti-eGFP 
antibodies. The result here demonstrated that the Kras was expressed as a fusion protein 
with molecular weight of approximately 50kDa (Kras ~ 21kDa; eGFP ~27 KDa; eGFP-
Kras ~ 48kDa), and was detectable with both anti-Kras and anti-eGFP antibodies (Figure 
3.3A).  
Active RAS-GTP binding assays (RBD-assay) were performed to ascertain that 
the eGFP-Kras G12V still retained its ability to interact with its effectors. The RAS 
binding domain (RBD) of Ral GDP dissociation stimulator (RalGDS) was used as a 
probe to “pull down” active GTP-bound Kras as described in Section 2.6. The RBD 
recognized the differences in the conformation of GST-RAS and GDP-RAS and had high 
affinity to GTP-bound RAS (active). The results in Figure 3.3B illustrated that the 
ectopically expressed GFP-Kras G12V was pulled-down by the RBD and detected by 
both the anti-Kras and anti-eGFP antibodies. Bacterial synthesized GST was used as a 
control to ensure that no non-specific binding to GST protein occurred. The results 
demonstrated that the ectopically expressed oncogenic Kras protein was active and able 




Figure 3.3: Oncogenic Kras G12V protein was expressed as an eGFP-tagged protein 
and retained its ability to interact with its effector. (A) Western blots of whole embryo 
lysates of eGFP positive and eGFP negative 5 dpf larvae. Both showed a band 
corresponding to approximately 50 kDa when probed with anti-Kras antibody and anti-
eGFP antibody, respectively, in the eGFP positive larval lysate (B) RBD pull-down assay 
followed by Western analysis indicates that the ectopically expressed eGFP-Kras G12V 
protein (~50 kDa) is GTP-bound and active. Blots were probed with anti-eGFP (rabbit) 
and developed; stripped and re-probed with anti-Kras (mouse) for the second 
development of blots.  
 
 
3.1.4 Oncogenic Kras expression caused enlargement of liver during development  
 It was observed that the liver-specific expression of eGFP-Kras G12V caused an 
enlargement of the organ during early development. To examine this Kras G12V-
mediated liver enlargement, volumetric analyses were performed. The Tg(lfabp-rtTA2s-
M2; TRE2-eGFP-Kras G12V) was crossed to the Tg(lfabp:dsRED; elaA:eGFP) named 
Lipan line (Korzh et al., 2008). The Lipan line constitutively expressed the dsRED 
83 
 
protein and eGFP in the liver and pancreas, respectively. Lipan line was used because of 
the need for a fluorescence reporter for the confocal imagining and volumetric 
quantification assay. The crossing of the two transgenic lines was performed to reduce 
the effect of genetic background and developmental speed/time. The embryos were 
induced with doxycycline at 2 dpf. The larvae were screened and selected for dsRED 
expression at 4 dpf and raised to 6 dpf. The dsRED positive larvae were screened for 
eGFP expression in the liver and separated into the eGFP positive and the eGFP negative 
group. The double transgenic (eGFP & dsRED) and single transgenic (dsRED) were used 
as a surrogate for the Tg(lfabp-rtTA2s-M2; TRE2-eGFP-Kras G12V) and wild-type age-
matched larvae, respectively. The specimen were prepared and imaged as described 
previously in Section 2.8. The result in Figure 3.4A demonstrated that ectopic expression 
of eGFP-Kras G12V caused a significant enlargement of the liver during early 







Figure 3.4: Oncogenic Kras expression in the liver caused an enlargement of the 
organ. (A) Volumetric analyses of the liver in the Lipan line vs Tg(lfabp-rtTA2s-M2; 
TRE2-eGFP-Kras G12V). Liver-specific expression of eGFP-Kras G12V caused 
significant increase in the organ volume (size) as compared to the control. (** denotes: p-
value <0.01; n=12). Error bars represent standard deviation. (B) Fluorescence (top panel) 
and bright-field images (bottom panel) of the Lipan line. (C) Fluorescence (top panel) 
and bright-field images (bottom panel) of the eGFP-Kras G12V transgenic larvae. (Scale 
bar: 250 μm.) 
 
 
3.1.5 Increased hepatocyte proliferation in eGFP-Kras G12V transgenic larvae 
 In order to determine if increased proliferation was the cause of enlargement of 
the liver, immunofluorescence staining with the proliferation marker, phospho-Histone3 
(pH3) was carried out. Cryostat sections obtained from 6 dpf larvae from out-cross of 
Tg(lfabp-rtTA2s-M2; TRE2-eGFP-Kras G12V) with wild-type fish were used. The 
results established that there was significant increase in proliferation of the hepatocytes in 
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the eGFP-Kras G12V expressing larvae compared to their wild-type siblings, as indicated 
by the significantly increased pH3 staining (Figure 3.5 B). 
 
Figure 3.5: Increased proliferation of the hepatocytes in Tg(lfabp-rtTA2s-M2; 
TRE2-eGFP-Kras G12V) larvae. (A) More pH3 positive cells were observed in the 
liver of the Tg(lfabp-rtTA2s-M2; TRE2-eGFP-Kras G12V) compared to wild-type. The 
wild-type liver is highlighted with yellow dotted line. The liver of Tg(lfabp-rtTA2s-M2; 
TRE2-eGFP-Kras G12V) is labelled green and highlighted with yellow dotted line. pH3 
positive cells were stained pink. (Scale bar: 50 μm.) (B) Proliferative index was scored 
based on number of pH3 stained cells over area occupied by the liver. The bar chart 
plotted relative ratio vs genotypes. The wild type is set as the reference value of one. 
Oncogenic Kras increased the hepatocyte proliferation significantly as compared to the 







3.1.6 Increased activity of RAF/MEK/ERK and PI3K/AKT pathways in eGFP-Kras 
G12V expressing larvae 
 As shown earlier, the liver overgrowth is largely due to the increase in 
proliferation in the eGFP-Kras G12V-expressing hepatocytes. Herein, I investigated if the 
two well-studied signaling cascades downstream of Kras are responsible for the increase 
in the liver overgrowth. RAF/MEK/ERK and the PI3K/AKT were well studied for the 
role in cell proliferation and cell survival, respectively. Western analyses were carried out 
to investigate the involvement of these two pathways. As shown in Figure 3.6 A, the level 
of phospho-Erk (an indicator of MEK/ERK activation) was increased in the eGFP-Kras 
G12V transgenic larvae as compared to the wild-type control. The level of total Erk 
remained relatively unchanged. As shown in Figure 3.6 B, the level of phospho-AKT2 
(an indicator of PI3K/AKT2 activation) and total AKT2 was increased in the eGFP-Kras 
G12V transgenic larvae as compared to the wild-type. Thus, these results suggested that 
the increased in RAF/MEK/Erk and PI3K/Akt2 activities, downstream of Ras signaling, 




Figure 3.6: eGFP-Kras G12V expression increased activation of the RAF/MEK/Erk 
and PI3K/Akt2 signaling. Larvae from out-cross of Tg(lfabp-rtTA2s-M2; TRE2-eGFP-
Kras G12V) with wild-type were used. Larvae were induced with doxycycline at 2 dpf, 
screened and harvested at 5 dpf for Western analysis. At least 50 larvae were pooled for 
each genotype (lane) per Western analysis. Immunoblots representative of at least three 
repeats. It was probed for phospho-Erk1/2, total Erk 1/2, phospho-Akt2 and total Akt2. 
(A) There was an increase in the amount of phospo-Erk1/2 in the eGFP-Kras G12V 
expressing larvae, while the total Erk 1/2 level remained relatively similar. (B) There was 
an increase in both the amount of phospho-Akt2 and Akt2 in the eGFP-Kras G12V larvae 
compared to the wild-type siblings. Anti-β-actin was used to demonstrate equal loading 







3.1.7 Inactivation of p21 (Cip1) by phosphorylation  
 I examined the involvement of p21 (Cip1), a downstream target of AKT2, in 
mediating the increase in proliferation. p21 (Cip1) is a potent cyclin-dependent kinase 
inhibitor and thus functions as a regulator of cell cycle progression. Western analysis was 
carried out with anti-phospho-p21 and anti-p21 antibodies with whole larvae lysates 
prepared as described in Section 2.5. As shown in Figure 3.7, there was an increase in the 
level of phospho-p21 in the Tg(lfabp-rtTA2s-M2; TRE2-eGFP-Kras G12V) larvae as 
compared to the wild-type siblings. The total amount of p21 remained unchanged in both 
samples. β-actin was used as a loading control.  
 
Figure 3.7: Akt2 inactivation of p21 (Cip1) as one of the possible mechanisms to 
promote cell growth. Larvae from out-cross of Tg(lfabp-rtTA2s-M2; TRE2-eGFP-Kras 
G12V) with wild-type were used. Larvae were induced with doxycycline at 2 dpf, 
screened and harvested at 5 dpf for Western analysis. At least 50 larvae were pooled for 
each genotype (lane) per Western analysis. Immunoblots representative of at least three 
repeats. It was probed with anti-phospho-p21 (Thr 145) and anti-p21. There was an 
increase in the level of phosphorylation of p21 in the eGFP-Kras G12V expressing 
larvae. β-actin and total p21 proteins were used to demonstrate equal loading.  
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3.2 Functional crosstalk between Kras and RhoA signaling 
 To study the functional crosstalk of Kras and RhoA in liver development and liver 
tumorigenesis, transgenic lines expressing RhoA (or its mutant) were required. The 
detailed strategy of RhoA transgenesis was described in the Section 2.3. 
 
 
3.2.1 Expression of the mCherry-RhoA transgene was both liver-specific and 
inducible 
 I investigated whether the mCherry-tagged RhoA transgene was exclusively 
expressed in the liver after induction. The F1 fish were out-crossed with wild-type fish. 
Embryos were collected, treated with doxycycline at 2 dpf and were allowed to develop 
until 6 dpf. The mCherry was used as reporter for the RhoA expression, which can be 
detected with fluorescence microscopy. As shown in Figure 3.8A to C, the mCherry 
expression was observed in the liver of the transgenic larvae specifically after induction 










Figure 3.8: Liver specific expression of mCherry-RhoA (or its mutants) upon 
induction. Lateral and ventral views of the larvae were documented. Respective 
genotypes of the larva are labelled on top. mCherry signals were restricted to the liver of 






3.2.2 Ectopically expressed mCherry –RhoA and its mutant were largely distributed 
in the cytosol  
 I aimed to determine the liver-specific expression and cellular distribution of the 
mCherry-tagged RhoA proteins. For this, I fixed and prepared 10 μm thick sections by 
cryostat sectioning as described in the Section 2.7. The sections were counterstained with 
DAPI and mounted for imaging. The images in Figure 3.9 showed that the ectopically 
expressed proteins (mCherry-RhoA, mCherry-RhoA T19N & mCherry-RhoA G14V) in 
the respective transgenic lines were restricted to the liver. The enlarged images further 
revealed that the mCherry-RhoA was distributed in the cytosol with numerous punctate-
like structures (Figure 3.9A iii & iv). Punctate distribution of the mCherry-RhoA T19N 
and mCherry-RhoA G14V in the cytosol were observed in Figure 3.9B (iii) and Figure 









Figure 3.9: Distribution of the mCherry tagged RhoA (or its mutants) after 
induction. Confocal images of cross sections of 6 dpf transgenic larvae - (A) RhoA, (B) 
RhoA T19N and (C) RhoA G14V. Panels iii and iv showed an enlargement of the picture 
in panels i and ii, respectively. (Panel iii of A) mCherry-RhoA was distributed in the 
cytosol with some punctate distribution. (Panel iii of B and C) Punctate distributions of 
the mCherry-tagged proteins in the cytoplasm were observed in the cross-section of 
mCherry-RhoA T19N and mCherry-RhoA G14V transgenic larvae. The sections were 





3.2.3 RhoA and its mutants were expressed as a mCherry-tagged protein 
 Liver lysate were harvested from respective transgenic fish that were treated with 
60 μg/ml of doxycycline for one week as described in Section 2.5.1. They were resolved 
with SDS-PAGE and probed with anti-RhoA and anti-GAPDH antibodies. The 
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immunoblot demonstrated bands at approximately 50 kDa that were reactive to anti-
RhoA antibody (Figure 3.10). RhoA and mCherry proteins are approximately 21 kDa and 
33 kDa, respectively. A fusion protein would be approximately 50 kDa in size. Here, I 




Figure 3.10 RhoA and its mutants were expressed as mCherry-tagged proteins. 
Immunoblots of the liver lysate analysed with Western probing for anti-RhoA antibody. 
Western demonstrated the detection of a band of 50 kDa in the respective RhoA 
transgenics, – (A) RhoA, (B) RhoA T19N and (C) RhoA G14V, but not in their 







3.2.4 Generation of double transgenic lines and their functional characterization  
 After the initial characterization of the three RhoA transgenic lines, I set to 
investigate their crosstalk with oncogenic Kras, especially during liver development and 
liver tumorigenesis. These can be achieved by crossing of the various RhoA transgenic 
lines (Tg(lfabp-rtTAs-M2; TRE2-mCherry-RhoA), Tg(lfabp-rtTAs-M2; TRE2-mCherry-
RhoA T19N) or Tg(lfabp-rtTAs-M2; TRE2-mCherry-RhoA G14V) with the Tg(lfabp-
rtTA2s-M2; TRE2-eGFP-Kras G12V) line to generate the double transgenic lines, 
respectively. Figure 3.11 illustrates the crossing strategy that was employed to generate 
the double transgenic lines. Only double transgenic larvae were shown. The double 
transgenic provided an invaluable tool to study the crosstalk of Ras and RhoA in an in 
vivo vertebrate model. Crosstalk between RAS and RhoA in an in vivo model was under-
appreciated as most studies were conducted in the in vitro cell model. For ease of 
labelling, the double transgenic will be labelled Kras G12V/RhoA for Tg(lfabp-rtTA2s-
M2; TRE2-eGFP-Kras G12V ; lfabp-rtTAs-M2; TRE2-mCherry-RhoA), Kras 
G12V/RhoA G14V for Tg(lfabp-rtTA2s-M2; TRE2-eGFP-Kras G12V ; lfabp-rtTAs-M2; 
TRE2-mCherry-RhoA G14V) and Kras G12V/RhoA T19N for Tg(lfabp-rtTA2s-M2; 





Figure 3.11: Schematic representation of simplified crossing of the Tg(lfabp-rtTAs-M2, TRE2-eGFP-Kras G12V) with the 
respective RhoA transgenic line. Double transgenic larvae were labelled with both mCherry and eGFP, and can be differentiated 
easily from their single transgenic or wild-type siblings. BF denotes bright-field. Simplified diagram for the purpose of illustrating the 
double transgenic larva from each cross. Scale bar is 500 μm for all images. 
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3.2.5 Effects of RhoA signaling on oncogenic Kras-mediated liver enlargement 
during development 
 As described earlier in Section 3.1.4 and 3.1.5, the ectopic expression of 
oncogenic Kras resulted in an enlargement of the liver during development, concomitant 
with elevated hepatocyte proliferation. Applying the same strategy of quantitative 
imaging, I investigated the effect of RhoA or its mutants on this oncogenic Kras-
mediated phenotype. Crosses were set up according to the scheme in Figure 3.11 for the 
respective genotypes. The larvae were treated with doxycycline at 2 dpf and sacrificed at 
6 dpf for imaging/documentation as described in the Section 2.8. 
 As shown in Figure 3.12 A, the dominant-negative mutant of RhoA T19N 
augmented the oncogenic Kras-mediated liver overgrowth significantly. The 
constitutively active RhoA G14V reduced the effect of Kras G12V mediated liver 
enlargement significantly, reducing it by up to 25% (Figure 3.12 B). No significant 
change in the liver volume of the double transgenic of Kras G12V/RhoA was observed as 
compared to the Kras G12V single transgenic (Figure 3.12 C).  
 
In addition, I investigated if the changes in the liver overgrowth were caused by 
any alterations in proliferation. Phospho-histone 3 staining was performed as described in 
Section 2.7.1. In Figure 3.13, the co-expression of RhoA T19N with Kras G12V 
increased the hepatocyte proliferation while the co-expression of RhoA G14V reduced 
the proliferation rate. Taken together, the blocking of RhoA signaling could enhance Kras 
G12V-driven proliferation thus resulting in a larger liver phenotype. Conversely, the 
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activation of RhoA signaling, in the background of activated Kras signaling, could reduce 














Figure 3.12: Volumetric analyses on the effect on RhoA signaling on Kras G12V 
mediated liver enlargement. The larvae were analyzed from the same family to account 
for the genetic background effects and variation in environment on growths. (A) RhoA 
T19N augmented the Kras G12V mediated liver enlargement significantly, (B) while the 
RhoA G12V reduced that, significantly. (C) No significant change in liver volume was 
observed in the double transgenic of Kras G12V/RhoA compared to the Kras G12V 
larvae. n ≥ 50 in Figure 3.12 B and C. n≥80 in Figure 3.12 A (** denotes p-value < 0.01). 






Figure 3.13: Effects of RhoA or its mutant on Kras G12V-induced hepatocyte 
proliferation. The proliferative index was scored based on phospho-histone3 staining on 
cryostat sections. It was defined as the number of pH3-positive cells over the area 
occupied by the liver. The bar chart plotted relative ratio vs genotypes. Kras G12V 
proliferative index was set as the reference value of one. Co-expression of RhoA T19N 
with Kras G12V caused a significant increase in the proliferation compared to Kras 
G12V. The co-expression of RhoA G14V with Kras G12V caused a reduction in the 
proliferation index compared to the Kras G12V. Co-expression of RhoA with oncogenic 
Kras did not affect the liver proliferation index significantly. (Different letters represent 






3.2.6 Impacts of RhoA signaling on oncogenic Kras-mediated AKT2 upregulation 
and activities 
 The induced expression of Kras G12V was demonstrated, earlier in Section 3.1.6, 
to upregulate Akt2 expression and activities. I investigated whether the Akt2 expression 
and activities were affected by the co-expression of RhoA, RhoA G14V or RhoA T19N. 
Consistent with the result presented in Figure 3.6 B, the induced expression of Kras 
G12V caused an increase in expression and activity of Akt2 compared to the wild-type 
siblings as shown in Figures 3.14 A to C. In Figure 3.14A, the dominant-negative RhoA 
T19N co-expression with Kras G12V caused an increase in the expression or activity of 
Akt2 as compared to the single transgenic larvae expressing Kras G12V only. In Figure 
3.14 B, the co-expression of constitutively active RhoA G14V with Kras G12V caused a 
decrease in both the expression and activity of Akt2 compared to the transgenic larvae 
expressing Kras G12V alone. The co-expression of RhoA with oncogenic Kras did not 










Figure 3.14: Co-expression of RhoA G14V with Kras G12V downregulated 
oncogenic Kras-induced Akt2 upregulation and activities. Whole larvae lysate of 5 
dpf larvae were used. Larvae were induced with doxycycline at 2 dpf, screened and 
harvested at 5 dpf for Western analysis. At least 50 larvae were pooled for each genotype 
(lane) per Western analysis. Immunoblots were representative of at least three repeats. 
(A) Co-expression of RhoA T19N with Kras G12V caused an increase in Akt2 
expression and activities. (B) Co-expression of RhoA G14V caused a significant 
reduction in oncogenic Kras induced AKT2 expression and activities. (C) Co-expression 
of RhoA did not affect the Kras G12V induced AKT2 expression and activities. Anti-Cox 





3.2.7 Oncogene-induced tumorigenesis/Survival study 
I carried out the survival study to answer the following: (1) does the expression of 
Kras G12V cause the development of HCC, (2) does RhoA or its mutants cause HCC 
development and (3) impacts of RhoA signaling on the Kras G12V-driven liver 
tumorigenesis, if any. This study was carried out as described in Section 2.3.1. 
 From the Kaplan-Meier survival curve in Figure 3.15, I observed the following, 
(1) 100% of the wild-type fish survived the doxycycline induction treatment, (2) 100% of 
the single RhoA transgenic fish survived the doxycycline induction treatment, (3) 
induction of Kras G12V expression in the liver caused a significant decrease in survival 
(p-value < 0.01, log rank test) compared to the wild-type and three single RhoA 
transgenic fish, (4) co-expression of RhoA or RhoA G14V with Kras G12V did not cause 
significant changes to the survival rate compared to the single transgenic expressing Kras 
G12V alone, (5) co-expression of RhoA T19N with Kras G12V caused a significant 
increase (p-value < 0.01, log rank test) in death rate compared to the single transgenic 
Kras G12V and the double transgenic line expressing either RhoA or RhoA G14V with 





Figure 3.15: Survival curve of the induction treatment. The graph shows days post 
induction plotted against percentage survival. The dosage of doxycycline used was 10 
μg/ml and the treatment was halted at 75 days. No death was observed in the wild-type 
and three single transgenic of RhoA, RhoA G12, and RhoA T19N after 75 days of 
treatment. The expression of Kras G12V (black line) in the liver caused a significant 
decline in survival as compared to the wild-type and the three single transgenic RhoA 
transgenic fish (grey line). The double transgenics of Kras G12V/RhoA T19N (blue line) 
accelerated death significantly compared to the single Kras G12V (black line); double 
transgenic Kras G12V/RhoA (red line) and Kras G12V/ RhoA G14V (yellow line). No 
significant changes were observed in the Kras G12V vs the double transgenic of Kras 
G12V/RhoA and Kras G12V/RhoA G14V, respectively. No death event was recorded for 




3.2.8 Over-expression of RhoA or its mutants did not cause liver malignancy 
 Dysregulation of RhoA, a master regulator of many biological processes, has 
always been implicated in the development and progression of tumorigenesis (Vega and 
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Ridley, 2008). Over-expression and over-activation of RhoA, over-expression of GEF 
and suppression of GAP have been reported in many human cancers (Gomez del Pulgar 
et al., 2005). One of the objectives in this study was to investigate the transforming 
properties of RhoA by the over-expression of RhoA or its mutants in the liver. From the 
survival curves described above, the induction of RhoA, RhoA G14V and RhoA T19N 
expression did not result in any death event. The single transgenic fish of RhoA, RhoA 
G14V and RhoA T19N were sampled, sacrificed, fixed and processed for histological 
analyses. The results in Figure 3.16 demonstrated that the induction of ectopic expression 
of RhoA or its mutants caused neither liver enlargement nor any liver lesion formation 




Figure 3.16: Over-expression of RhoA or its mutants did not induce the formation of liver malignancy. The genotypes of the 
fish and the treatment dosages of doxycycline were labelled with the treatment dosages of doxycycline at the top. (A-D) Gross 
observations of the various fish. (E-H) The fish were dissected to show the size of the liver. The livers are highlighted with the dotted 
yellow line. There was no obvious enlargement of the liver in transgenic fish compared to the wild-type control. (I-L) H&E stained 
paraffin sections. No significant lesion was observed in the single transgenic fish. The scale bar for Figures 3.16 A to H is one cm. The 




3.2.9 Liver-specific expression of Kras G12V caused HCC development 
Next, I investigated whether the liver-specific ectopic expression of oncogenic 
Kras G12V can result in the formation of malignancies in the zebrafish, which resulted in 
the significant increase in death rate. As shown in Figure 3.17 G, the ectopic expression 
of eGFP-Kras G12V was able to induce the development of HCC. It was possibly driven 
by the increased proliferation of the hepatocytes as demonstrated by the increased PCNA 
staining (Figure 3.17 J) as compared to the controls (Figure 3.17 K and L). The increased 
proliferation of the hepatocytes also contributed to liver overgrowth as shown in Figure 
3.17 D. Wild type fish were used as the control which demonstrated that the exposure to 
doxycycline did not cause the development of malignancies. Tg(lfabp-rtTA2s-M2; TRE2-
eGFP-Kras G12V) siblings in the no-doxycycline treatment control group were also used 
as the control to demonstrate that the induced expression of the eGFP-Kras G12V is 







Figure 3.17: Formation of hepatocellular carcinomas (HCC) upon the induction of 
the eGFP-Kras G12V transgene in the Tg(lfabp-rtTA2s-M2; TRE2-eGFP-Kras 
G12V) adult fish. The genotypes of the fish and treatment dosages of doxycycline are 
labelled with the treatment dosages of doxycycline at the top. eGFP-Kras G12V denotes 
the Tg(lfabp-rtTA2s-M2; TRE2-eGFP-Kras G12V) line. (A-C) Gross observations of the 
various fish. (D-F) The fish were dissected to illustrate the size of the liver. The livers are 
highlighted with the dotted yellow line. There was obvious enlargement of the liver in 
Figure 3.17 D as compared to Figures 3.17 E & F. (G-I) H&E staining of the paraffin 
sections. Figure 3.17 G illustrate the development of lesions that are characteristic of 
HCC, while the Figures 3.17 H & I showed no significant lesions. (J-L) 
Immunohistochemical (IHC) staining of the paraffin section with proliferation marker, 
PCNA (brown). Figures 3.8J showed a significant increase in the staining as compared to 
the Figures 3.17 K & L. The scale bar for Figures 3.17 A to F is one cm. The scale bar for 
Figures 3.17 G to L is 50μm. 
 
 
3.2.10 Erk activation was upregulated in the oncogenic Kras-driven HCC  
 From the observation of the increased proliferation of the hepatocytes in the 
treated Tg(lfabp-rtTA2s-M2; TRE2-eGFP-Kras G12V), I investigated whether 
proliferation-related Erk signaling was upregulated in oncogenic Kras-mediated HCC. 
Immunofluorescence staining was performed as described in Section 2.9.1. As 
demonstrated in Figure 3.18, there was an increase in the MEK/Erk activation as 
indicated by the increase in phospho-Erk1/2 staining in the HCC samples as compared to 
the wild-type controls. The phospho-Erk1/2 staining was mainly observed in the nucleus 
of the hepatocytes. It was also observed that the upregulation of the MEK/Erk signaling 






Figure 3.18: Increased Raf/MEK/Erk signaling in the Tg(lfabp-rtTA2s-M2; TRE2-
eGFP-Kras G12V) as compared to the wild type control. The genotypes of the fish are 
labelled on the left side and the treatment dosages of doxycycline are in parentheses. 
eGFP-Kras G12V denotes the Tg(lfabp-rtTA2s-M2; TRE2-eGFP-Kras G12V) line. The 
paraffin sections were with anti-pErk1/2 (green). The stainings of the phosho-Erk1/2 
were mainly observed in the nucleus. DIC images were used to illustrate the liver. The 
scale bar is 50 μm.  
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3.2.11 Alteration in RhoA signaling affected the rate of developing liver 
malignancies but not the outcome of oncogenic Kras-mediated transformation 
 I sought to determine whether the death of the fish was due to the development of 
liver lesions/malignancies or related complications in the double transgenic lines. Fresh 
dead fish or sick-sacrificed fish were fixed and processed for H&E and IHC staining. Due 
to practical reasons, sampling was performed and not all fixed specimens were analyzed.  
In Figure 3.19, the oncogenic Kras expressing transgenic lines were observed 
with enlarged liver (Figure 3.19 E to H) and diagnosed with HCC (Figure 3.19 I to L) 
associated with increased proliferation. Table 10 summarizes the findings (diagnosis) of 
the four transgenic lines (illustrated in Figure 3.19) that showed significant increase in 
death rate compared to the wild-type control in the induction treatment group (Section 
3.2.7, Figure 3.15). All the fish sampled in these four groups developed various liver 
lesions, described in Table 5, which could be the underlying cause(s) of death. All of the 
double transgenic Kras G12V/RhoA T19N sampled fish were diagnosed with HCC. They 
also have higher proliferation rate (Figure 3.19 N) compared to the other three genotypes 
analysed (Figure 3.19 M, O and P), as determined by the PCNA staining. 90% of the 
single Kras G12V transgenic line developed HCC. 70% and 50% of the double transgenic 
Kras G12V/RhoA G14V and double transgenic Kras G12V/RhoA developed HCC, 
respectively. Samples that were not diagnosed with HCC were either diagnosed with 
hepatocellular adenoma or hyperplasia. The three double transgenic lines did not develop 




Moreover, I demonstrated that without the induced expression of the transgene by 
doxycycline, the transgenic fish did not develop HCC or significant liver lesion 







Figure 3.19: Induction of liver tumors in transgenic zebrafish. The genotypes and 
dosage of doxycycline are labelled on top of the images. The fish with the most severe 
phenotypes are represented in this Figure. (A-D) Gross observations from the left of the 
respective fish. (E-H) Fish showing abdominal internal organs, with the liver highlighted 
in the yellow dotted lines. All fish had enlarged liver compared to the wild-type (Figure 
3.17E). (I-L) H&E staining of the Bouin’s-fixed paraffin sections which displayed 
characteristic features of HCC. (M-P) IHC staining performed with PCNA to demonstrate 
the increased proliferation in the HCC samples. More PCNA positive were observed in 
the Kras G12V/RhoA T19N (Figure 3.19 N) compared to the other three genotypes. 
Slides were counterstained with hematoxylin. The scale bars for A to H are one cm, I to L 
are 50 μm and M to P are 100 μm. 
 
 
Table 10: Summary of diagnosis on selected transgenic fish treated with 10μg/ml 
doxycycline 
Genotype Died fish/ 
total 
number 



















 HCC HCA/HP 
Kras G12V 28/40 
(70%) 





























Figure 3.20: Non doxycycline-treated transgenic fish did not develop HCC. The genotypes and dosage of doxycycline are labelled 
on top of the images. No doxycycline was added in this batch (A-D) Gross observations of the left side of the respective fish. (E-H) 
Fish showing abdominal internal organs, with the liver highlighted with yellow dotted lines. No significant change in the liver size 
was observed. (I-L) H&E staining of Bouin’s fixed paraffin sections. No significant lesions were observed in the H&E stained slides. 











Chapter 4  Discussion and Conclusion  
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4.1 Modeling HCC in zebrafish 
 Since the identification of RAS as an oncogene nearly three decades ago, 
numerous efforts and researches have been carried out in attempt to elucidate the role of 
RAS and its associated signaling cascades in human malignancies. Pioneering work on 
RAS in the in vitro cell-based systems defined the transforming ability of RAS and the 
importance of its downstream effectors signaling cascade in mediating such 
transformation, in particularly the RAF/MAPK and PI3K/AKT pathways (Cox and Der, 
2010; Malumbres and Barbacid, 2003).  
In recent years, genetically modified mouse models have been instrumental in 
unraveling how deregulated RAS signaling leads to tumorigenesis (Karreth and Tuveson, 
2009). There is an obvious lack of mouse models in modeling human liver cancers with 
the RAS oncogene. To date, there is only one study describing the effect of oncogenic 
HRas in mediating HCC formation only in the presence of a β-catenin mutation (Harada 
et al., 2004). This could be partly attributed to the lower percentage of human liver 
cancers being associated to the mutation of the RAS gene. Up to 60% of pancreatic 
cancers were attributed to the mutation of the KRAS while only 5% of human liver 
cancers were found with the activating mutation in the KRAS (Pylayeva-Gupta et al., 
2011). Coupled with the increasing relevance of the zebrafish as an alternative animal 
model for the modeling of human liver cancers (Lam and Gong, 2006; Lam et al., 2006), 
we generated the first in vivo liver cancer (HCC) model driven by inducible Tet-on 
ectopic expression of oncogenic Kras G12V in the zebrafish [Tg(lfabp-rtTA2s-M2; 




4.1.1 Characterization of the Tg(lfabp-rtTA2s-M2; TRE2-eGFP-Kras G12V) 
The inducible Tet-on system was employed for this study because it provides two 
main advantages. Firstly, inducible systems reduce the problem of maintenance of the 
animal as the constitutive expression of the oncogenic Kras could result in early lethality. 
It was reported that transgenic mice expressing high levels of oncogenic HRAS in the 
liver suffered from enlarged liver at birth and died shortly thereafter (Sandgren et al., 
1989). Secondly, it allows me, the investigator, to control the spatial and temporal 
expression of the transgene through the use of tissue-specific promoters. As described in 
Figure 3.1, the expression of eGFP was observed exclusively in the liver only after 
induction by doxycycline. Although the leaky expression of the Tet-on system has been 
reported by in the zebrafish (Huang et al., 2005), neither leaky expression in the absence 
of doxycycline nor mis-targeted expression in the presence of doxycycline was observed 
in our transgenic line, Tg(lfabp-rtTA2s-M2; TRE2-eGFP-Kras G12V). With the eGFP 
reporter, the transgenic fish could be separated from their wild-type siblings by simple 
visual inspection with a fluorescence dissecting microscope.  
Western blot analysis of the whole larvae lysates (Figure 3.3 A) revealed that the 
oncogenic Kras G12V was expressed as an eGFP-tagged protein in the transgenic line. 
Thus, the eGFP expression can be used as an indicator for the expression of the 
oncogenic Kras G12V. I further demonstrated that the ectopically expressed eGFP-Kras 
G12V protein was predominantly localized to the plasma membrane (Figure 3.2). KRAS, 
like the HRAS and NRAS, had to be plasma membrane-bound for effective signaling to 
take place, in particularly for growth and transformation related processes (Hancock, 
2003). Plasma membrane bound oncogenic KRAS-induced transformation, while 
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mitochondrial membrane-bound oncogenic KRAS cause apoptosis through a BCL-XL 
dependent manner (Bivona et al., 2006). Non-plasma membrane bound HRAS is less 
effective in the activation of the RAF, PI3K and JNK than plasma membrane bound 
HRAS, and resulted in loss of 25 to 90% of its transforming ability in NIH3T3 focus 
assays (Chiu et al., 2002; Hancock, 2003; Hancock et al., 1990). 
The ectopically expressed oncogenic Kras was enriched in an active-RAS RDB 
pull-down assay (Figure 3.3 B). These indicated that the ectopically expressed Kras 
G12V can be loaded with GTP, activated and retains the ability to bind and interact with 
its effector.  
Further evidence documenting the activities of the ectopically expressed 
oncogenic Kras were provided as illustrated in Figure 3.6. The activities of downstream 
RAF/MAPK and PI3K/Akt2 signaling cascade were measured by probing for the 
phosphorylated species of Erk1/2 and AKT2, respectively. Both Erk1/2 and Akt2 were 
activated through activating phosphorylation by their respective upstream kinase. 
Activities of both the Erk1/2 and Akt2 were increased in eGFP-Kras G12V expressing 
larvae compared to their wild-type siblings. This faithfully recapitulates the effects of 
aberrant RAS signaling observed in previous in vitro and in vivo studies. 
 MAPK signaling was found to be both sufficient and necessary to induce cellular 
transformation in mouse cell lines (Leevers et al., 1994; Stokoe et al., 1994; White et al., 
1995). Activated Erk1/2 has been known to activate transcription factors, driving 
expression of growth-related proteins. The importance of MAPK signaling in human 
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cancers can be inferred through the oncogenic mutations found in receptor tyrosine 
kinases, RAS and RAF, and its upstream regulators (Karreth and Tuveson, 2009).  
Like the MAPK pathway, hyperactivation of AKT had also been frequently found 
in many human cancers, which was not surprising as AKT regulates many different 
cellular processes including cell proliferation, cell survival, cell size, angiogenesis and 
invasion (Altomare and Testa, 2005). Interestingly, in the case of Akt2, the protein level 
was also elevated in Figure 3.6 B. AKT2 expression level is reported to be up-regulated 
in many human cancers and the increased expression is correlated to higher pathological 
grades, such as hepatocellular carcinoma, colon cancers, squamous cell carcinomas, 
gliomas and etc (Mure et al., 2010; O'Shaughnessy et al., 2007; Roy et al., 2002; Xu et 
al., 2004).  
There are three isoforms of AKT found in human, namely AKT1, AKT2 and 
AKT3. I only probed for the activity of Akt2 and not all three isoforms in this study 
because of the following reasons. Firstly, there was a lack of useful antibodies available 
for research in zebrafish as many commercially available antibodies only works for the 
higher vertebrate species like mouse, rat and human. Secondly, to date, Akt2 (Q802Y3) is 
the only one of the three isoforms that was characterized and studied in zebrafish. Our 
laboratory has demonstrated that the Kras/PI3K/Akt2 signaling is important for the 
zebrafish hematopoiesis and angiogenesis during early development (Liu et al., 2008). It 
was also shown that Akt2 is important for modulating glucose availability/homeostasis, 
by regulating glut1 gene expression, during early zebrafish development (Jensen et al., 
2010). Thirdly, until now, the Akt1 and Akt3 proteins remain relatively uncharacterized 
in zebrafish. Akt1 was only predicted to exist based on predication (source: Uniprot). 
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Akt3 is found at the protein level and two paralogs were present, namely akt3a and akt3b. 
Akt3 is the only isoform in the zebrafish to be found with paralogous gene. Lastly, there 
was no data available to illustrate the isoform selectivity (of activation) by the RAS/PI3K 
signaling cascade (Gonzalez and McGraw, 2009).  
 
 
4.1.2 Kras G12V caused liver overgrowth in developing larvae 
By means of bioimaging and image processing, I demonstrated that the ectopic 
expression of eGFP-Kras G12V was able to cause liver overgrowth during development 
compared to the control (Figure 3.4). This liver enlargement can be attributed to the 
increased hepatocyte proliferation as shown by an increased staining by anti phospho-
histone 3 antibody, a mitotic marker (Figure 3.5). This increased proliferation was the 
result of oncogenic Kras signaling. As discussed earlier, cell proliferation related 
downstream signaling cascades of Kras activation, MAPK/Erk and PI3K/Akt pathways, 
were found to be upregulated in the eGFP-Kras G12V expressing transgenic larvae. In 
addition, increased amount of p21 (Cip) (a potent cell cycle progression inhibitor) was 
found to be inactivated by phosphorylation at Thr145 (Figure 3.7). AKT-mediated 
inhibitory phosphorylation at threonine 145 has been reported to be a negative regulator 
of its function and disrupted its inhibitory interaction with proliferating cell nuclear 
antigen (PCNA) (Li et al., 2002; Rossig et al., 2001; Zhang et al., 2007), thus promoting 
proliferation and cell survival. Phosphorylation of p21 (Cip) at Thr 145 by AKT caused 
the protein to residue in the cytosol, thus preventing its inhibitory interaction with the 
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cyclin-dependent kinase (CDK) or PCNA (Zhou et al., 2001). Taken together, the 
ectopically expressed oncogenic Kras activated the RAF/MAPK and PI3K/AKT 




4.1.3 HCC development caused by expression of oncogenic Kras 
The liver-specific expression of oncogenic Kras in the adult zebrafish drove the 
formation of HCC in the transgenic fish (Figure 3.17). The transgenic fish that developed 
HCC displayed enlarged livers and increased proliferation (PCNA staining in Figures 
3.17 J-L) as compared to the controls. Immunofluorescence staining with anti-phospho-
Erk1/2 demonstrated that the activity of Erk1/2 was increased in the oncogenic Kras 
driven HCC (Figure 3.18). The phospho-Erk1/2 was largely localized in the nucleus, 
which concur with current knowledge that the activated Erk1/2 needs to translocate into 
the nucleus for activating transcription factor for mitogenic responses (Mebratu and 
Tesfaigzi, 2009). Impaired nucleus translocation of activated Erk1/2 (cytosolic retention) 
not only reduced cell proliferation and survival signals, but at the same time also 







4.1.4 Summary of the Tg(lfabp-rtTA2s-M2; TRE2-eGFP-Kras G12V) 
 I demonstrated that the transgenic zebrafish, Tg(lfabp-rtTA2s-M2; TRE2-eGFP-
Kras G12V) line, is a robust and unique model for modeling human liver cancer. The 
induction of oncogenic Kras expression led to the development of HCC. This correlates 
well with the phenotypic change of liver enlargement during early development. Thus, 
this model, in the larval stage, is very suitable for high throughput small-chemical 
compound screening. Potential drug candidates could be screened for their efficacy in 
inhibiting oncogenic Kras-mediated responses/phenotypes and signaling cascades, for 
example, in reducing the size of the liver enlargement. The screening performed on the 
larvae has an added advantage compared to the in vitro cell-based screening, as chemical 
compounds with embryonic developmental toxicity can be picked out earlier. Thus, it can 
reduce the attrition rate during the long and expensive drug development process.  
 
 
4.2 Crosstalk of Kras and RhoA in mediating liver development and hepato-
tumorigenesis 
 RAS and Rho GTPases are master regulators of numerous biological events, with 
many overlapping processes, for example, proliferation and survival. Their crosstalk in 
regulating tumorigenesis has been intensively investigated over the last two decades, but 
remains largely limited to cell-based studies. The only exception was a study carried out 
in the drosophila model by Brumby and co-workers (2011) for the study of crosstalk of 
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RAS and Rho. Despite the many reported studies, the role of RhoA in RAS-mediated 
tumorigenesis remains highly contentious. To date, there is no reported study of this 




4.2.1 Generation of RhoA transgenic lines 
 To study the crosstalk of Kras and RhoA in regulating liver tumorigenesis, 
transgenic lines expressing RhoA, constitutively active RhoA G14V or dominant-
negative RhoA T19N were generated, respectively. The maize Ac/Ds transposase system 
was employed for transgenesis because of the reported high efficacy in zebrafish 
transgenesis (Emelyanov et al., 2006). One single plasmid vector (Figure 2.2 A) 
harboring both the transactivator and the response element was used instead of two 
separate plasmid vectors each with either the transactivator or the response element. This 
is to ensure a more stable transmission of both the transactivator and the response 
element to the future progeny of the transgenic fish. I consistently achieved germline 
transmission rates of 6.67% for all three RhoA transgenic lines. It is much lower than the 
60% reported when the Ac/Ds transposase system was applied to the zebrafish 
(Emelyanov et al., 2006). It could be attributed to the higher DNA load (larger DNA 
insert) in my system compared to their studies.  
 I successfully generated three transgenic lines that express mCherry-RhoA, 
mCherry-RhoA G14V and mCherry RhoA T19N, respectively. As demonstrated in 
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Figures 3.8 and 3.9, the transgenic larvae expressed mCherry in a liver-restricted manner 
upon induction by doxycycline. The confocal images of cryostat sections of the 
respective transgenic larvae further demonstrated that the punctuate distribution of the 
ectopically expressed mCherry RhoA, mCherry RhoA T19N and mCherry RhoA G14V 
proteins. Similar punctuate distribution of the RhoA proteins were also observed/reported 
in many other studies (Covian-Nares et al., 2004; Hehnly et al., 2009; Kulkarni et al., 
2002; Woodside et al., 2003). It was further ascertained by Western analysis that the 
three variants of the RhoA transgene were expressed as mCherry-fusion proteins (Figure 
3.10), thus the usefulness of mCherry as a reporter for the transgenes expression. 
 
 
4.2.2 Impact of RhoA signaling on Kras G12V induced liver overgrowth in 
developing larvae 
I generated double transgenic lines, by crossing the Tg(lfabp-rtTA2s-M2; TRE2-
eGFP-Kras G12V) with the respective RhoA transgenic lines, to study the impact of 
RhoA signaling on oncogenic Kras transformation of the liver (Figure 3.11). 
Like many earlier studies on the function of RhoA, constitutively active and 
dominant-negative mutants of RhoA were employed in this study in addition to RhoA. 
RhoA shares high sequence identity with the two closely related proteins, RhoB and 
RhoC. The motifs and domains for their interaction with regulators and effectors are 
rather conserved, which could result in their extensive overlapping interactions with 
RhoGEFs, RhoGAPs and/or target proteins (Wheeler and Ridley, 2004). As such, it raises 
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the possibility of functional interference by non-specific activation or inhibition of 
closely related members. For example, the use of dominant-negative RhoA T19N could 
result in the inhibition of all three Rho members. Likewise, the use of RhoA G14V could 
result in the activation of all three Rho effectors (Wang and Zheng, 2007). Nevertheless, 
in view of the lack of feasible knockout technology and mutagenesis methods to silence 
or activate RhoA in zebrafish, respectively, the use of dominant-negative and 
constitutively active mutants of RhoA still remain an attractive and viable option to study 
RhoA function in liver tumorigenesis. The use of the ectopic expression of activating and 
inhibitory mutants has an added advantage in the zebrafish. RhoA has five paralogous 
genes present in the zebrafish genome. The ectopic expression of mutants is less likely to 
be affected by the presence of paralogous genes, unlike the case of morpholinos studies, 
which may affect the results. 
Leveraging on the knowledge that the ectopic expression of oncogenic Kras 
caused liver overgrowth in the developing larvae and the methods devised to measure 
liver size quantitatively in the larvae, the impact of the co-expression of RhoA or its 
mutants with Kras G12V were investigated during early development. Here, I reported 
that the co-expression of RhoA T19N (together with Kras G12V) augmented Kras-
mediated liver overgrowth significantly (Figure 3.12 A) coupled with the increased 
hepatocyte proliferation (Figure 3.13), while the co-expression of RhoA G14V with Kras 
G12V caused a significant reduction in the liver overgrowth by oncogenic Kras (Figure 
3.12 B) together with a significant decrease in hepatocyte proliferation (Figure 3.13). 
However, the co-expression of RhoA with Kras G12V did not affect the liver overgrowth 
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and proliferation rate, significantly (Figures 3.12 C and 3.13) and served as an internal 
control for the effects of RhoA on oncogenic Kras signaling. 
These observed effects of RhoA on proliferation have also been reported by other 
researchers. The inactivation of RhoA activities by the dominant-negative T19N mutant 
was associated with a higher rate of proliferation of hematopoietic progenitor cells, via 
decreased p21 Cip expression and increased cyclin-D1 level (Ghiaur et al., 2006). The 
proliferation restrain imposed on osteoblasts which were grown on calcium phosphate 
apatite surface, through increased RhoA activities, can be reversed by the inhibition of 
RhoA/ROCK signaling (Yang et al., 2011). Moreover, the abilities of RhoA signaling to 
retard proliferation were also reported in two other studies. Activation of RhoA by 
vasopressin (vasoactive peptide hormone) downregulated cyclin-D1 expression, which 
resulted in the inhibition of oncogenic KRAS-driven proliferation (Forti and Armelin, 
2007). In the other study, it was demonstrated that the ectopic expression of RhoA G14V 
inhibited proliferation by slowing down the G1 to S phase cell cycle transition and 
hindering the completion of cytokinesis. It was also shown by the authors that the active 
RhoA could impair MAPK pathway activation and the downregulation of cell cycle and 
cytokinesis-related proteins like the epithelial cell transforming sequence 2 and cyclinB1 
(Morin et al., 2009). 
Here, I conclude that the inhibition of RhoA signaling could potentiate oncogenic 
Kras-mediated proliferative effects in the liver; while the activation of RhoA signaling 
had an inhibitive effect on oncogenic Kras-mediated hepatocyte proliferation.  
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 My findings on this crosstalk of RAS and Rho in regulating liver growth did not 
concur well with the findings of the majority of studies where RhoA activation favors 
RAS transformation, as summarized in Table 3. However, it is worthwhile to note that all 
of these studies, which demonstrated the requirement of active RhoA in RAS 
transformation, utilized the HRAS isoforms instead of the KRAS isoform investigated in 
this study. Furthermore, all except one of those studies used the fibroblast cell type 
instead of epithelial cell type which the hepatocyte belonged to. It was reported that the 
fibroblast cell type responded differently from the epithelial cell type when activated 
RAS is introduced. It was even suggested by the authors that the fibroblast is an 
inappropriate model for RAS-induced transformation (Skinner et al., 2004). Interestingly, 
two out of the four studies that supported our findings employed the KRAS mutants in 
their experimental setup, and one of these two studies utilized an epithelial cell type for 
their investigation (Dreissigacker et al., 2006; Shah et al., 2001). It was suggested that 
this crosstalk of RAS and Rho depends on the cell-types, the RAS isoforms, and the 
duration of RAS activation (Chen et al., 2003). All the studies summarized in Table 3 
were conducted in an in vitro cell based setting except for the Drosophila study. 
Therefore, it is of paramount importance that I addressed this crosstalk between Kras and 
RhoA in an in vivo animal model.  
 In this study, I have also identified the Akt2 pathway as a possible target for 
regulation by RhoA signaling. I have established that the ectopic expression of Kras 
G12V could lead to an increase in Akt2 expression and activities. The co-expression of 
RhoA G14V with Kras G12V led to a decrease in both the expression and overall 
activities of Akt2 compared to the single transgenic of Kras G12V (Figure 3.14 B). This 
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result coincides with the previous data that the co-expression of RhoA G14V with Kras 
G12V caused a reduction in hepatocyte proliferation and liver size. Constitutively active 
RhoA was reported to inhibit AKT activation through the Rho kinase-dependent pathway 
(Ming et al., 2002). The decreased activities of Akt2 could also be an indirect effect of 
active RhoA on the expression level of Akt2. RhoA has been known to modulate the 
expression of various proteins, such as epithelial nitric oxide synthase, p21 and p27 
(Chen et al., 2003; Ming et al., 2002; Olson et al., 1998; Vidal et al., 2002). RhoA has 
also been shown to be able to regulate the activities of various transcription factors, for 
example, GATA4, AP-1, NF-κB, and serum-response factor (Chang et al., 1998; Charron 
et al., 2001; Hill et al., 1995; Perona et al., 1997). Therefore it is not surprising that the 
constitutively active RhoA was able to downregulate Akt2 expression induced by 
oncogenic Kras in my study.  
 In addition, I have also reported the increase in expression and activities of the 
Akt2 in the double transgenic - Kras G12V/RhoA T19N. Increased Akt activation by 
phosphorylation in response to the inactivation of RhoA signaling had been described in 
two separate studies. Inhibition of the ROCK, a key effector of RhoA signaling, by Y-
27362 treatment led to an increase in Akt activation (Yang et al., 2011). The ectopic 
expression of RhoA T19N in murine prostate cancer cells caused an increase in the 






4.2.3 Impact of RhoA signaling on Kras G12V-induced liver tumors 
 To further investigate the effects of RhoA signaling on the Kras-induced HCC 
formation, induction treatment was carried out in the adult fish. The outcomes of this 
induction treatment were analyzed by a Kaplan-meier plot (Figure 3.15) and 
histopathological examination (Figures 3.16, 3.17, 3.19 and 3.20; Table 10).  
 All the fish in the control group (eight genotypes) without doxycycline treatment 
survived the 75 days treatment. Selected genotypes (corresponding to the genotypes that 
had significant death rate compared to the wild-type control in the doxycycline induced 
group) were processed, H&E stained and analysed. As demonstrated in Figure 3.20, the 
transgenic fish did not have enlarged liver and did not develop any significant liver 
lesion. These indicated that the expression of the Kras G12V transgene was necessary for 
the transformation to occur.  
 The wild-type control doxycycline-treated group did not differ in the survival rate 
from the wild-type control in the non-treated control group after 75 days of treatment. 
The survival rate of the wild-type controls in both treatments was at 100%. 
Histopathological examination of the liver in the doxycycline-treated wild-type controls 
revealed no significant liver lesions (Figures 3.16 and 3.17). Therefore, we can deduce 
that the exposure to doxycycline did not contribute to the development of any liver 
lesion.  
 All the single RhoA, RhoA G14V and RhoA T19N transgenic fish survived the 
doxycycline induction treatment (Figure 3.15). In addition, histopathological examination 
of the liver revealed that there was no significant lesion presented (Figure 3.16 I to K). 
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Thus, I deduced that the ectopic expression of RhoA or its mutants (RhoA G14V or 
RhoA T19N) did not result in the development of liver tumors. 
  The survival rate of the single Kras G12V transgenic fish was significantly lower 
(log-rank test: p-value < 0.01) than the wild-type control upon doxycycline induction. 
The gross observation and histopathological analysis demonstrated the presence of 
features typical of HCC (Figures 3.17 A, D & G; Figures 3.19A, E & I).  
Consistent with the earlier findings in the liver proliferation and overgrowth in the 
larvae, the adult double transgenic of Kras G12V/RhoA T19N exhibited a significantly 
higher mortality rate compared to the single transgenic of Kras G12V (Figure 3.15). The 
proliferation rate was also elevated in the double transgenic Kras G12V/RhoA T19N 
compared to the single transgenic Kras G12V as indicated by the PCNA staining (Figure 
3.19 N and M, respectively). Despite the increased death rate of the double transgenic 
Kras G12V/RhoA T19N compared to the single Kras G12V transgenic, it did not 
translate into a more severe phenotype (higher grade HCC or invasive). It could be 
because the zebrafish could have died before the HCC could develop further. It indicated 
that the blockage of RhoA signaling by dominant-negative RhoA T19N could potentiate 
and accelerate the rate of Kras G12V-mediated tumorigenesis.  
The co-expression of RhoA with Kras G12V did not exhibit any significant 
differences in the survival rate compared to the single Kras G12V transgenic fish (Figure 
3.15). It is consistent with the results presented earlier in Section 3.2.5, where the co-
expression RhoA with Kras G12V did not affect the Kras-mediated liver overgrowth.  
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Interestingly, the co-expression of RhoA G14V with Kras G12V did not show any 
significant differences in its survival rate compared to the single Kras G12V. It must be 
noted that the survival curve of the double transgenic Kras G12V/RhoA G14V has a 
gentler gradient and a larger median value compared to the single Kras G12V but the 
differences between the two curves were not statistically significant as determined by the 
log rank test (p-value > 0.05). A larger sample size or a longer duration of treatment may 
be required for the differences to be statistically significant. These observations did not 
concur with previous findings in the larvae presented in Section 3.2.5. This could be 
attributed to the differences in the inherent molecular machineries present in the different 
life stages of the zebrafish, specifically the larvae and the adult fish.  
It is worthwhile to note that no metastasis or invasion of the carcinoma was 
observed in all histological specimen analyzed. The transgenic fish might have 
succumbed to the Kras G12V-driven tumorigenesis before the disease can develop 
further. This could also be attributed to the inducer, doxycycline, used for this study. 
Doxycycline had been reported to downregulate several matrix metalloproteinases 
(MMPs) expression and inhibit their activities (Duivenvoorden et al., 2002; Saikali and 
Singh, 2003). MMPs play important roles in tumor invasion and metastasis. Many studies 
have reported that doxycycline can reduce the invasiveness of various cancer cells such 
as colorectal cancer, prostate cancer, oral squamous cell carcinoma, cervical cancer, 
breast cancer and ovarian cancer lines, via downregulation of the MMPs and/or inhibiting 
their activities (Duivenvoorden et al., 2002; Lokeshwar, 1999; Onoda et al., 2004; Roomi 
et al., 2010; Saikali and Singh, 2003; Shen et al., 2010).  
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In summary, I presented an in vivo zebrafish HCC model driven by oncogenic 
Kras for modeling human HCC. This oncogenic Kras-driven model faithfully 
recapitulates the activation of major downstream signaling cascades, for example the 
RAF/MAPK and PI3K/AKT pathways. Thus it can be used as tool for the identification 
of novel signaling pathway/effectors of RAS signaling. These could be essential for a 
more detailed understanding of RAS-driven hepato-oncogenicity. This transgenic line is 
unique in the sense that there is strong correlation of the liver overgrowth in the larval 
stage with the development of HCC in the adult stage. This uniqueness could be explored 
for small chemical compound screening to identify compounds that can suppress RAS 
signaling. I have also presented the zebrafish as an alternative in vivo model for studying 
small GTPase signaling and interplay. I have presented evidence that the inhibition of 
RhoA signaling accelerates/augments Kras-mediated liver overgrowth and tumorigenesis. 
This could caution the development and application of therapeutics directed at inhibiting 
RhoA signaling in Kras-driven tumors. With these, I presented the first vertebrate in vivo 
study of the crosstalk of Ras and Rho in regulating liver development and liver 
tumorigenesis. Herein, I propose the following models in Figure 4.1 A and B to illustrate 







Figure 4.1: Proposed model of crosstalk between Ras and Rho in liver development 
and HCC formation. (A) Kras G12V caused liver overgrowth through the activation of 
the Raf/MAPK and PI3K/Akt2 pathways. RhoA G14V caused a reduction in liver 
enlargement possibly through the reduction in PI3K/Akt2 signaling. RhoA T19N 
enhanced liver enlargement probably through the increase in PI3K/Akt signaling output. 
(B) Kras G12V caused the formation of HCC in adult upon induction. It could be partly 
attributed to the increased Raf/MAPK signaling leading to increased proliferation. The 
co-expression of RhoA T19N accelerated Kras G12V-mediated HCC formation through 




4.3 Limitations  
One of the main problems encountered in this study was the lack of suitable 
antibodies that were reactive against the zebrafish proteins of interest. This largely 
limited the different pathways that I could study with our model.  
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Transgenesis is an attractive way of studying the effects of certain genes in 
various biological processes. Along with it comes the problem of managing the side-
effect of having the transgene inserted into regions (coding region, promoter, DNA 
elements) where it could disrupt gene expression and thus functions. The knowledge on 
the number of insertions and the sites of integration could provide useful information by 
deciphering if there were chances of any by-product. To reduce the possibility of 
observations being just by-products, one could use more than one transgenic line for the 
same transgene of interest to verify the outcomes. However, this was not performed in 
this study because of the practical reasons like the limitation of resources.  
Another drawback of this study is the use of the over-expression system. Ectopic 
expressions of protein, which exceed physiological levels, are often criticized for being a 
misrepresentation of the real events. However, it is currently one of the most feasible 
ways of studying the tumorigenesis effects of an oncogene. The advancement in this field 
such as the TALENs offered great potential to create targeted mutations at the gene of 
interest. But much work needs to be done to have a better understanding and control of 
the TALENs system. Until then, transgenesis by ectopic expression will remain as the 
choice of method in this type of study.  
 
4.4 Future perspectives 
Is there Akt isoform-specificity in oncogenic Kras signaling? 
I demonstrated that the ectopic expression of oncogenic Kras in the liver resulted 
in the upregulation of Akt2 expression and activities, which contributed to increased liver 
136 
 
overgrowth. The introduction of RhoA G14V in the background of oncogenic Kras 
signaling reduced the Kras G12V-mediated liver overgrowth along with a decrease in 
both expression and activities of Akt2. Interestingly, one of my colleagues has 
demonstrated that knock-down of Akt2 using anti-sense technology led to the under-
development of the liver during embryogenesis (Liu Lihui, unpublished data). This 
implies the importance of Akt2 in regulating liver development. We could assess the 
effect of Akt2 knock-down in our oncogenic Kras transgenic to study its role in liver 
overgrowth in our transgenic model.  
The isoform specificity of the activation by the PI3K downstream of RAS 
signaling remains poorly defined to date (Gonzalez and McGraw, 2009). The knock-
down of the three isoforms can be carried out separately in the Tg(lfabp-rtTA2s-M2; 
TRE2-eGFP-Kras G12V) line to assess its individual role in oncogenic Kras signaling. 
These could provide more insight into the specificity of the different AKT isoform in 
driving oncogenic Ras signaling. 
 
Crosstalk of Ras and Rho in other tissues 
 Aberrant KRAS signaling caused by the activating mutation of the KRAS can be 
found in approximately 25% of all human cancers (Bos, 1989; Karnoub and Weinberg, 
2008; Pylayeva-Gupta et al., 2011). Approximately 60% of all pancreatic cancers were 
found to be attributed to the mutation in the KRAS (Table 1). Other studies have also 
demonstrated the oncogenicity of Kras in eliciting pancreas tumorigenesis in zebrafish 
(Park et al., 2008). Thus, it will be interesting to address the crosstalk of RAS and Rho in 
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the pancreas, or any other organs in Kras-mediated transformation. This will ultimately 
help us better understand whether cell type specificity exists for this crosstalk.  
  
Interactions with other oncogenes and tumor suppressor genes 
 My study showed that transgenic zebrafish are useful for studying signaling 
crosstalk and functional interplay of two different proteins. I also verified that the Kras 
transgenic line is a good model for studying liver tumorigenesis. Making the oncogenic 
Kras as the focus, we can study functional interplay of other oncogenes (C-myc gene, 
WNT, RTK, cyclin D1, cyclin E) and tumor suppressor genes (DLC-1, PTEN, 
Retinoblastoma protein, p53) with oncogenic Kras in causing and preventing HCC 
formation. 
 
Knockdown and knockout of RhoA 
The suppression of RhoA signaling, through the use of a dominant-negative 
mutant, augmented the oncogenic Kras effects on liver growth and HCC development as 
demonstrated in this study. To further ascertain the specificity of this interaction, a 
knockout or knockdown will be complementary. So far, the knockout technology in the 
zebrafish is still very much at its infant stage, with the likes of zinc finger nucleases and 
TALENs showing promising results. However, this technology is not readily available to 
the community due to its high cost and complexity. Therefore, the best way is to focus on 
the larvae liver growth. Morpholino anti-sense technology can be employed to 
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knockdown RhoA in the Kras transgenic to assess the effects of the loss of RhoA 
signaling on Kras-induced liver overgrowth. However, it must be noted that RhoA is an 
important regulator of processes during early embryogenesis. Therefore there is a 
possibility that the knockdown of RhoA could result in early developmental defects that 
could confound the results.  
 
How is oncogenic Kras-activated RAF/MAPK signaling affected by RhoA signaling 
during liver overgrowth? 
 I reported the decreased activities of the PI3K/AKT2, as one of the effectors of 
Kras, being affected by the activation/inactivation of RhoA (Section 3.2.6, Figure 3.14) 
in the double transgenic lines (liver), which manifested in the reduction/increase of liver 
overgrowth caused by Kras G12V. There are many other important effectors of Kras that 
have not been studied in this study, namely, the RAF/MAPK pathway. Future works can 
seek to address the perturbation of this pathway activated by oncogenic Kras signaling by 
active RhoA through Western analysis. 
 
Transgenic zebrafish larvae as an excellent drug screening tool 
To have a better understanding of the pathways involved, specific chemical 
inhibitors of various pathways can be applied to the transgenic fish. For example, in this 
study, the RAF/MAPK/Erk and PI3K/AKT2 pathways were upregulated in the presence 
of oncogenic Kras signaling. Chemical inhibitors such as the U0126 and Wortmannin 
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which inhibit the MEK1/2 and PI3K respectively can be employed. These could provide 
evidences on the requirements of various pathways in driving Kras-mediated liver 
overgrowth. This would provide the proof of concept that the model is suitable for small 
chemical screening.  
The oncogenic Kras transgenic line is a unique model where there is high 
correlation of the phenotypic changes in the larvae with the development of HCC in the 
adult. Thus, this raises the feasibility of using it as a high throughput drug screening tool. 
Small chemical compound libraries can be readily applied to the transgenic larvae to 
assess the effect of the various compounds on oncogenic Kras signaling. In addition, the 
compound can be screened for their teratogenic effects simultaneously. 
 
IHC approaches to a more accurate diagnosis 
In order to achieve a higher level of confidence in the diagnosis of the histological 
samples, we could perform IHC for certain prognostic and diagnostic markers on the 
specimens of interest. It was demonstrated in a study that E-cadherin, matrix 
metalloproteinase-7 and matrix metalloproteinase-9 immuno-histochemistry can be used 
to differentiate human normal liver, HCC and HCA based on the differences in the 
staining intensity of the three antibodies (Tretiakova et al., 2009). If applicable to the 
zebrafish liver cancer model, it can greatly improve the accuracy of the diagnosis of the 
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